

CURRICULUM VITAE

WEST, Michael Lindsay
Department of Medicine

PERSONAL:

Born: Grostenquin, France, June 19, 1953.
Citizenship: Canadian

ACADEMIC CREDENTIALS:

1975 BSc (Hons), Biology, Queen's University, Kingston, Ontario
1979 MD, Queen's University, Kingston, Ontario

OTHER CREDENTIALS:

1984 Royal College of Physicians and Surgeons of Canada Certification in Internal Medicine (FRCPC)
1984 Certificat of American Board of Internal Medicine
1985 Royal College of Physicians and Surgeons of Canada, Certificate of Special Competence in Nephrology
1989 Fellow of American College of Physicians (FACP)

APPOINTMENTS AND PROMOTIONS:

College of Medicine, University of Saskatchewan, Saskatoon

1986 (July) Assistant Professor, Department of Medicine, Division of Nephrology
1989 (April) Associate Professor, Department of Medicine, Division of Nephrology

Faculty of Medicine, Dalhousie University, Halifax, N.S.

1990 (July) Associate Professor, Department of Medicine, Division of Nephrology
1996 Tenure
1998-2003 Director, Nephrology Training Program
2001 (July 1st) Professor, Department of Medicine, Division of Nephrology
2003-2009 Head, Division of Nephrology
2011-present Assistant Dean, Research-Clinical Trials

HONOURS (MEDALS, FELLOWSHIPS, PRIZES):

1971 Ontario Scholar Award, Ottawa, Ontario
1976 Dwyer Memorial Scholarship, Queen's University, Kingston, Ontario
1977 Steacy Memorial Scholarship, Queen's University, Kingston, Ontario
1979 Aesculapian Award, Queen's Medical Student Society, Queen's University, Kingston, ON.
1985 Clinical Research Society of Toronto, Research Essay, Second Prize, Toronto, ON.
1984-1986 Medical Research Council of Canada Research Fellowship
1989 Clinical Teacher of the Year, Department of Medicine, College of Medicine,

- University of Saskatchewan, Saskatoon, Saskatchewan
- 1995** Excellence Award for Undergraduate Teaching, Department of Medicine, Dalhousie University, Halifax, NS
- 1996** President's Award, Nova Scotia Branch, Kidney Foundation of Canada, Halifax, NS.
- 1997** Excellence Award for Undergraduate Teaching, Department of Medicine, Dalhousie University, Halifax, NS.
- 1999** Excellence Award for Undergraduate Teaching, Department of Medicine, Dalhousie University, Halifax, NS.
- 2000** Excellence Award for Undergraduate Teaching, Department of Medicine, Dalhousie University, Halifax, NS.
- 2001** Excellence Award for Undergraduate Teaching, Department of Medicine, Dalhousie University, Halifax, NS.
- 2002** Best Clinical Study, 2nd International Symposium on Lysosomal Storage Diseases, Cannes, France, April 26-27, 2002.
- 2009** Best Clinical Study, 9th International Symposium on Lysosomal Storage Diseases, Frankfurt, Germany, April 24-25, 2009.
- 2009** Best Clinical Poster Presentation, Fabry Nephropathy Satellite of the World Congress of Nephrology, Bergamo Italy, May 27-28, 2009.
- 2010** Most highly cited article Molecular Genetics and Metabolism 2008-2011.
- 2011** Winner of Best Resident Clinical Poster, Department of Medicine Research Day 2011. Winner of Best Poster, Faculty of Medicine Resident Research Day 2011. Supervisor of Dr. Marion Cornish, medical resident.
- 2012** Winner of Andrew Herzenberg Award for Best Nephropathology or Transplant Pathology Abstract, Canadian Association of Pathology Annual Meeting, Calgary AB. Supervisor of Dr. Talal Alfaadhel, nephrology resident.
- 2014** 3rd Prize Poster Award, 5 Year Outcomes in the Canadian Fabry Disease Initiative Study. Fabry Expert Lounge Meeting, Rome, Italy. March 21, 22, 2014
- 2015** Winner of Best Resident Poster, Aortic Dissection-a Complication of Fabry Disease? Department of Pathology Research Day May 1, 2015. Supervisor of Dr. Michael Carter, pathology resident.

POSITIONS PREVIOUS TO DALHOUSIE UNIVERSITY EMPLOYMENT:

- 1986-1990** Assistant/Associate Professor, Division of Nephrology, Department of Medicine, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan
- 1984-1986** Medical Research Council of Canada Fellowship, St. Michael's Hospital, University of Toronto, Toronto, Ontario. Dr. ML Halperin, Supervisor.
- 1983-1984** Nephrology Resident, University of Toronto, St. Michael's and Toronto Western Hospitals, Toronto, Ontario
- 1980-1983** Resident, Department of Medicine, Dalhousie University, Halifax, N.S.
- 1980** Rotating Internship, Dalhousie University, Halifax, N.S.

TEACHING RESPONSIBILITIES AT THE UNIVERSITY OF SASKATCHEWAN, COLLEGE OF MEDICINE, SASKATOON, SASK.: (Course No.,

Course Name)	
1986-1990	401/501 Clinical Sciences (4-6 lectures/year)
1986-1988	303.6 Physiology (3 lectures/year)
1986-1990	401/501.33 Clinical Sciences (Clinical Tutor) (24 hours/year)
1987-1988	302.6 Clinical Sciences (Clinical Tutor) (22 hours/year)
1988-1990	203.3 Clinical Correlations (Clinical Tutor) (6 hours/year)
1986-1990	Nephrology Noon Teaching Rounds (1/month)
1986-1990	Acid-Base, Electrolyte Seminars (52/year)
1986-1990	ICU Nephrology Rounds (1/4 weeks)
1986-1989	Medical Grand Rounds
May 15, 1987	Potassium Homeostasis in Hyperglycemic Disorders
Mar 9, 1988	Dietary Therapy of Chronic Renal Disease
Jan 18, 1989	Membranous Glomerulonephritis: What to Do Until the Data Arrive;
May 24, 1989	Diabetic Nephropathy: Is End Stage Renal Disease Preventable?
Jun 13, 1990	rHu-EPO-Recombinant Human Erythropoietin, A Milestone In Nephrology.
1986-1990	Renal Biopsy Rounds (1/month)
1987-1990	Senior Resident Bedside Teaching Rounds (3/year)
Oct. 31, 1989	Medical Resident Basic Science Seminar: Atrial Natriuretic Factor
1986-1989	JURSI Therapeutic Seminar (2/year)
1986-1990	Annual LMCC Nephrology Review
1990	Renal Radiology Rounds (1/month)

**TEACHING RESPONSIBILITIES AT DALHOUSIE UNIVERSITY,
FACULTY OF MEDICINE, HALIFAX, N.S.**

1990-present	Coordinator, Monthly Renal Biopsy Conference, Victoria General Hospital Site
1990-1995	Nephrology Teaching Seminar (Clerks, PGY1-5) (weekly)
1990-91, 1991-92	Med III Clinical Bedside Teaching (8 Weeks/year)
1990-present	Medicine Clerkship (Med III, IV) Clinical Supervisor, Nephrology Service (1-3 clerks/year)
1991-1992	Coordinator, Renal Transplant Education Program
1991-1993	Med III Renal Tutorials (6 hours/year)
1991-1992	Med I Renal Physiology Lectures on Potassium, Osmolality and Acid Base Regulation (4 hours)
1992-1999	Med II Renal Component, Head
1992-1999	Med I Bedside Clinical Tutor (63 hours/year)
1992-1995	Med IV Nephrology Exam Review (4 hours/year)
1994-2001	Urology Clerkship Nephrology Tutorials (12 hours/year)
1995-1999	Med II Genitourinary, Gastrointestinal, Musculoskeletal Unit, Head
1996-2001	Critical Care Lecture Series, Electrolyte Disorders (1 hour/year)
1992-present	Med II COPS Curriculum, GGM Unit, Renal-Urology Component Lecturer (1-5 hours/year), Resource person, Examiner, Pathology Laboratory Tutor, Acid-base Electrolyte Workshop Tutor
1992-1997	Med II COPS Curriculum, GGM Unit, Renal-Urology Component Head

	and Unit Head
1995-2004	Department of Medicine, PGY4 Practice Oral, Examiner
1996-1997	Med IV Clinical Pharmacology Unit Tutor and Resource Person (6 hours/year)
1997-2003	Med II OSCE, Examiner
1997-present	Department of Medicine, Internal Medicine Residency Training Program OSCE, Examiner (3 hours/year)
1999-present	Department of Medicine, Medical Clerkship OSCE, Examiner (3 hours/year)
1999-2004, 2006-7, 2010-12, 2014	Med II General Medicine Bedside Tutor (27-35 hours/year)
2002, 2010	LMCC Part II Examiner
2002-2010	Med I Metabolism and Function Unit Renal Physiology Lecturer (2-4 hours per year)
2002-2014	Acid-base, Electrolyte Problems, Resident Academic Half Day, Department of Medicine
2011-2012	Med II Metabolism: Kidney: Lecturer, Measurement of Renal function (1hour/year)
2014-present	Med II Metabolism: Kidney: Lecturer, Drugs and the Kidney (1hour/year)

THESES/STUDENTS SUPERVISED:

1989	Sharon Bailey, University of Saskatchewan, College of Medicine 1989 Summer Research Project: Evaluation of Glomerular Hematuria by Coulter Counter and Phase Contrast Microscopy.
Apr. 2, 1993	External Examiner, MSc Thesis. Peter Papadogianis, Department of Pathology, Dalhousie University, Halifax, NS. Altered Expression of Corticosteroid Binding Globulin (CBG) in a Mouse Model of Polycystic Kidney Disease.
June 22, 1993	Examiner, PhD Thesis. Yongdong You, Department of Physiology and Biophysics, Dalhousie University, Halifax, NS. Effects of Ischemia and Preservation Solutions on Morphology and Transport of Renal Proximal Tubules.
May 2010	Supervisor Dr. Turki AlAmeel, Medical Resident. Tranexamic acid treatment of life-threatening hematuria in polycystic kidney disease.
May and June 2011	Supervisor Dr. Marion Cornish, Medical Resident. Department of Medicine Research Day and Faculty of Medicine Resident Research Day.
Oct. 22, 2014	Becca Webster, Memorial University of Newfoundland, Faculty of Medicine, ST. John's NL. Special Projects II-MED 6770. The Canadian Fabry Disease Initiative: a review.

May 1, 2015

Co-supervisor of Dr. Michael Carter, pathology resident Poster Presentation: Aortic Dissection-a Complication of Fabry Disease? Department of Pathology Research Day.

BOOKS, CHAPTERS IN BOOK AND REVIEW ARTICLES

1. **WEST ML.** Disorders of Serum Potassium. Medicine (North America) 1988, 28:5200-5214.
2. **WEST M.** The Canadian Society of Nephrology: The Later Years, 1983-2000. The Canadian Society of Nephrology, A Millennium Anthology. 2001.
3. **WEST ML.** Fabry's Disease: a rare, X-linked, lysosomal storage disorder. Parkhurst Exchange. 2005, 13(1):78-81.
4. Warnock DG, Valbuena C, **WEST M** and Oliveira JP. Renal Manifestations of Fabry Disease in Fabry Disease, eds Elstein D, Altarescu G, Beck M. Springer 2010.
5. **WEST M,** Linthorst, G. Fabry Disease in Inherited Metabolic Disease in Adults, eds. Hollak CEM, Lachman R. Oxford University Press, 2016.

PUBLICATIONS

1. Halperin ML, Marsden PA, Singer GG, **WEST ML.** Does marked hyperglycemia occur without ketosis? Clin Invest Med 1985;8:253-256.
2. **WEST ML,** Marsden PA, Richardson RMA., Zettle RM, Singer GG, Halperin ML. New clinical approach to evaluate disorders of potassium secretion. Min Electrolyte Metab 1986;12:234-238.
3. **WEST ML,** Bendz O, Chen CB, Singer GG, Richardson RMA, Sonnenberg H, Halperin ML. Development of a test to evaluate the transtubular potassium concentration gradient in the cortical collecting duct in vivo. Min Electrol Metab 1986;12:226-233.
4. Halperin ML, Chen CB, Cheema-Dhadli S, **WEST ML,** Jungas RL. Is urea formation regulated primarily by acid-base balance *in vivo*? Am J Physiol 1986;250:F605-612.
5. **WEST ML,** Marsden PA, Singer GG, Halperin ML. A quantitative analysis of glucose loss during therapy for the hyperglycemic hyperosmolar syndrome. Diab Care 1986;9:465-471.
6. Halperin ML, **WEST ML.** Diabetic ketoacidosis presenting with a normal anion gap. (Letter). American Journal of Medicine 1986;81:1115-1116.
7. **WEST ML,** MacSween JM, Rajaraman K, Cohen AD. Lymphokine responses in renal transplant recipients with and without malignancy. Transplant Proc 1986;18:218-220.

8. **WEST ML**, Sonnenberg H, Veress A, Halperin ML. The relationship between the plasma potassium concentration and renal potassium excretion in the adrenalectomized rat. *Clinical Science* 1987;72:577-583.
9. **WEST ML**, Jindal KK, Bear RA, Goldstein MB. A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis, the nephrotic syndrome and impaired renal function. *Kidney Int* 1987;32:579-584.
10. Zettle RM, **WEST ML**, Josse RG, Richardson RMA, Marsden PA, Halperin ML. Renal potassium handling during states of low aldosterone bio-activity: a method to differentiate renal and non-renal causes. *Am J Nephrol* 1987;7:360-366.
11. Zettle RM, **WEST ML**, Chen CB, Halperin ML. Does the kidney "escape" from the kaliuretic action of mineralocorticoids? *Min Electrolyte Metab* 1987;13:340-346.
12. Halperin ML, Margolis BL, Robinson LA, Halperin RM, **WEST ML**, Bear RA. The urine osmolar gap: a clue to estimate urine ammonium in "hybrid" types of metabolic acidosis. *Clin Invest Med* 1988;11:198-202.
13. Dyck RF, **WEST ML**, Owen PS. Quiz of the Month: A patient with hyperkalemia. *Am J Nephrol* 1988;8:347-348.
14. **WEST ML**, Magner PO, Richardson RMA, Halperin ML. A renal mechanism limiting the degree of potassium loss in severely hyperglycemic patients. *Am J Nephrol* 1988;8:373-378.
15. Leiter LA, Josse RG, **WEST ML**, Halperin ML. Severe metabolic acidosis induced in a patient by kcl administration. *Clin Invest Med* 1988;11:266-270.
16. Ethier J, Magner PO, Kamel KK, **WEST ML**, Halperin ML. Évaluation clinique de la sécrétion rénale de potassium: une nouvelle méthode non invasive. *Médecine Sciences* 1988;4:637-642.
17. Baltzan MA, Baltzan RB, Baltzan BL, Cunningham TA, Pylypchuk GB, Dyck RF, **WEST ML**. HLA matching enhances long-term renal graft survival but does not relate to acute rejection. *Medicine (Baltimore)* 1990;69:227-231.
18. Dyck RF, Asthana S, Kalra J, **WEST ML**, Massey KL. A modification of the urine osmolal gap: an improved method for estimating urine ammonium. *Am J Nephrol* 1990;10:359-362.
19. Jindal K, **WEST M**, Bear R, Goldstein M. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. *Am J Kid Dis* 1992;19:61-67.

20. Hirsch DJ, **WEST ML**, Cohen AD, Jindal KK. Experience with not offering dialysis to patients with a poor prognosis. *Am J Kid Dis* 1994;23:463-466.
21. Sketris I, Waite N, Grobler K, **WEST M**, Gerus S. Factors affecting compliance with cyclosporine in adult renal transplant patients. *Transplant Proc* 1994;26:2537-2540.
22. **WEST M**, Bell D. The Anuric Septuagenarian - George MacIverson. *Med II COPS Curriculum Case and Tutor Guide*. 1994, Faculty of Medicine, Dalhousie University, Halifax, NS.
23. **WEST M**. The Wayward Weightlifter - William Chisholm. *Med II COPS Curriculum Case and Tutor Guide*. 1994, Faculty of Medicine, Dalhousie University, Halifax, NS.
24. Sketris IS, Wright MR, **WEST ML**. Possible role of the intestinal p-450 enzyme system in a cyclosporine - clarithromycin interaction. *Pharmacotherapy* 1996;16:301-305.
25. Sepandj F, Jindal K, **WEST M**, Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anemia in chronic hemodialysis patients. *Nephrol Dial Transplant* 1996;11:319-322
26. **WEST M**. Jennifer Sampson: Hypertension Through the Ages. *Med IV COPS Curriculum Case Tutor Guide*. 1996, Faculty of Medicine, Dalhousie University, Halifax, NS.
27. Waite NM, Sketris I, Grobler K, **WEST M**, Gerus S. Renal transplant recipient response to a cyclosporine use survey at two Canadian centres. *Can J Hospital Pharmacy* 1996;49:191-196.
28. Mendelssohn DC for the Professional and Public Policy Committee of the Canadian Society of the Canadian Society of Nephrology (incl. **M. WEST**). Principles of end-stage renal disease care. *Ann RCPSC* 1997;30:271-273.
29. Crocker JFS, **WEST ML** Jason Jacobi: the Irritable Child. *Med II COPS Curriculum Case and Tutor Guide*. 1998. Dalhousie University, Halifax, NS.
30. Kareemi M., Mosher D., **WEST M**. The Aching Housewife: Anita Bonner *Med II COPS Curriculum Case and Tutor Guide*. 1999. Dalhousie University, Halifax, NS.
31. **WEST M**, Bell D. Cornelius McMartin: the Unlucky Passenger. *Med II COPS Curriculum Case and Tutor Guide*. 2000. Dalhousie University, Halifax, NS.
32. **WEST M**, Kareemi M. Lucy, the Girl with Kaleidoscope Eyes. *Med II COPS Curriculum Case and Tutor Guide*. 2001. Dalhousie University, Halifax, NS.

33. Thadhani R, Wolf M, **WEST ML**, Tonelli M, Ruthazer R, Pastores GM, Obrador GT. Patients with Fabry disease on dialysis in the United States. *Kidney International* 2002; 61: 249-255.
34. **WEST M**, Crocker JFS. Sam Dhali, The Obstructed Child. Med II COPS Curriculum Case and Tutor Guide. 2002. Dalhousie University, Halifax, NS.
35. **WEST ML**, Wolf HK. Fuming Joe. Med I COPS Curriculum Case and Tutor Guide. Nov 2002. Dalhousie University, Halifax NS.
36. Warnock DG, **WEST ML**. Diagnosis and management of kidney involvement in Fabry disease. *Advances in Chronic Kidney Disease* 2006;13:138-47.
37. **WEST ML** Breathless Bill. Med I COPS Curriculum Case and Tutor Guide. Jan. 2007. Dalhousie University, Halifax NS.
38. Clarke JT, **WEST ML**, Bultas J, Schiffmann R. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. *Genetic Medicine* 2007;9:504-9.
39. **WEST M**, Byers D. Robert Hart: Return of the Prodigal Son. (a case of Fabry disease) Med I COPS Curriculum Case and Tutor Guide. Metabolism and Function Unit, Sept. 2007. Dalhousie University, Halifax NS.
40. Banikazemi M, Bultas J, Waldek S, Wilcox W, Whitley C, McDonald M, Finkel R, Packman S, Bichet D, Warnock D Desnick R for the Fabry Disease Clinical Trial Group (**including WEST M**). Agalsidase-beta therapy for advanced Fabry disease. A randomized trial. *Ann Intern Med* 2007;146:77-86.
41. Bichet D, Casey R, Clarke JTF, Sirrs S, **WEST ML**. The Canadian Fabry Disease Initiative Annual Report 2006-7. www.cihr-irsc.gc.ca/e/35799
42. Auray-Blais C, Cyr D, Ntwari A, **WEST ML**, Cox-Brinkman J, Bichet DG, Germain DP, Laframboise R, Melançon SB, Stockley T, Clarke JTR, Drouin R. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. *Mol Genet Metab* 2008; 93:331-40. Top cited article *Molecular Genetics and Metabolism* 2008-2010.
43. Feriozzi S, Schwarting A, Sunder-Plassmann G, **WEST M**, Cybulla M, on behalf of the FOS Investigators. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. *Am J Nephrol* 2009;29:353-361.
44. **WEST M**, Nicholls K, Mehta A, Clarke JTR, Steiner R, Beck M, Barshop B, Rhead W, Mensah R, Ries M, Schiffmann R. Agalsidase alfa and kidney dysfunction in Fabry disease. *J Am Soc Nephrol* 2009;20:1132-1139.

45. **WEST ML**, Bichet D, Casey R, Clarke JTF, Sirrs S. The Canadian Fabry Disease Initiative Annual Report 2007-8. <http://www.cihr-irsc.gc.ca/e/39586.html>
46. Fogo A, Bostad L, Svarstad E, Cook W, Moll S, Barbey F, Geldenhuys L, **WEST M**, Ferluga D, Vujkovic B, Howie A, Burns A, Reeve R, Waldek S, Noel L-H, Grunflod J-P, Valbuena C, Oliveira J, Muller J, Breunig F, Zhang X, Warnock D. Scoring system for renal pathology in Fabry disease: Report of the International Study Group of Fabry Nephropathy (ISGFN). *Nephrol Dial Transplant* 2010;25:2168-2177.
47. Sirrs S, Clarke JTR, Bichet DG, Casey R, Lemoine K, Flowerdew G, Sinasac DS, **WEST ML**. Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative. *Mol Genetics Metab* 2010;99:367-373.
48. Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, **WEST M**, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A. A validated disease severity scoring system for Fabry disease. *Mol Genetics Metab* 2010; 99:283-290.
49. Warnock DG, Daina E, Remuzzi G, **WEST M**. Enzyme Replacement Therapy and Fabry Nephropathy. *Clin J Am Soc Nephrol* 2010; 5:371-378.
50. Mehta A, **WEST M**, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores G, Lidove O. Therapeutic goals in the treatment of Fabry Disease. *Genetics in Medicine* 2010;12:713-720.
51. Lidove O, **WEST ML**, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A. Effects of enzyme replacement therapy in Fabry disease-A comprehensive review of the medical literature. *Genetics in Medicine* 2010;12:668-679.
52. Auray-Blais C, Ntwari A, Clarke JT, Warnock DG, Oliveira JP, Young SP, Millington DS, Bichet DG, Sirrs S, **WEST ML**, Casey R, Hwu WL, Keutzer JM, Zhang XK, Gagnon R. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? *Clin Chim Acta*. 2010; 411(23-24):1906-14.
53. Morgunov NS, **WEST ML**. Mary Rollins: A case of Central Diabetes Insipidus. *Med II Metabolism Curriculum Case and Tutor Guide*, Dalhousie University, Halifax NS. 2011.
54. Patel M, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, **WEST M** et al. Cardiovascular events in patients with Fabry disease: natural history data from the Fabry registry. *J Am Coll Cardiol* 2011;57:1093-9.
55. AlAmeel T, **WEST M**. Tranexamic acid treatment of life-threatening hematuria in polycystic kidney disease. *International Journal of Nephrology* 2011; Article ID 203579,

3 pages. doi:10.4061/2011/203579

56. Feriozzi S, Torras J, Cybulla M, Nicholls K, Sunder-Plassmann G, **WEST M** on behalf of the FOS Investigators. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. *Clin J Am Soc Nephrol* 2012;7:60–69.
57. Hughes DA, Malmenäs M, Deegan PB, Elliott PM, Ginsberg L, Hajooff D, Ioannidis AS, Orteu CH, Ramaswami U, **WEST M**, Pastores GM, Jenkinson C. on behalf of the FOS Investigators. Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease. *J Med Genet.* 2012;49:212-220.
58. **WEST M**, Bichet D, Casey R, Clarke J, Sirrs S on behalf of the CFDI Investigators. Canadian Fabry Disease Initiative Year Five Annual Report. Oct. 1, 2010 to September 8, 2011. Submitted to the provincial governments of Canada.
59. **WEST M**, Bichet D, Casey R, Clarke J, Iwanochko M, Moore D, Sirrs S. Canadian Fabry Disease Treatment Guidelines 2011. <http://www.garrod.ca/wp-content/uploads/FD-Treatment-Guidelines-2011.pdf>
60. Linthorst GE, Burlina AP, Cecchi F, Cox TM, Fletcher JM, Feldt-Rasmussen U, Giuliani R, Kantola I, Lachmann R, Lopez M, Ortiz A, Parini R, Rivera A, Rolfs A, Ramaswami U, Svarstad E, Tondel C, Tyłki-Szymanska A, Vujkovic B, Waldek S, **WEST M**, Weidemann F, Mehta A. Recommendations on reintroduction of agalsidase beta for patients with Fabry disease in Europe, following a period of shortage. *JIMD Reports* 2012;5:51-56.
61. Cybulla M, Kurschat C, **WEST M**, Nicholls K, Torras J, Sunder-Plassmann G, Feriozzi S on behalf of the FOS Investigators. Kidney Transplantation and Enzyme Replacement Therapy in Patients with Fabry Disease. *J Nephrol.* 2013;26:645-51.
62. Schiffmann R, Ries M, Blankenship D, Nicholls K, Mehta A, Clarke JT, Steiner RD, Beck M, Barshop BA, Rhead W, **WEST M**, Martin R, Amato D, Nair N, Huertas P. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa. *Genet Med.* 2013;15:983-9.
63. **WEST ML** content expert for Gout: Update 2013, Dalhousie CME Academic Detailing Service, November 2013, http://cme.medicine.dal.ca/ad_resources.htm
64. Sirrs SM, Bichet DG, Casey R, Clarke JTR, LeMoine K, Doucette S and **WEST ML**. Outcomes of patients treated through the Canadian Fabry Disease Initiative. *Molecular Genetics and Metabolism* 2014;111:499-506.
65. van der Tol L, Cassiman D, Houge G, Janssen MC, Lachmann RH, Linthorst GE, Ramaswami U, Sommer C, Tøndel C, **WEST ML**, Weidemann F, Wijburg FA, Svarstad E, Hollak CEM, Biegstraaten M. Uncertain diagnosis of Fabry disease in patients with

- neuropathic pain, angiokeratoma or cornea verticillata: Consensus on the approach to diagnosis and follow-up. *Journal Inherited Metabolic Disease Reports* 2014;17:83-90.
66. Auray-Blais C, Blais CM, Ramaswami U, Boutin M, Germain DP, Dyack S, Bodamer O, Pintos-Morell G, Clarke JT, Bichet DG, Warnock DG, Echevarria L, **WEST ML**, Lavoie P. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. *Clin Chim Acta*. 2015;438:195-204.
67. Mauer M, Glynn E, Svarstad E, Tondel C, Gubler M-C, **WEST M**, Sokolovskly A, Whitley C, Najafian B. Mosaicism of podocyte involvement is related to podocyte injury in females injury in females with Fabry disease. *PLoS One* 2014;9(11):e112188. doi: 10.1371/journal.pone.0112188
68. Smid BE, van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, Timmermans J, Weidemann F, **WEST ML**, Biegstraaten M, Lekanne Deprez RH, Florquin S, Postema PG, Tomberli B, van der Wal AC, van den Bergh Weerman MA, Hollak CE. Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. *Int J Cardiol*. 2014 Dec;177:400-8.
69. van der Tol L, Svarstad E, Ortiz A, Tøndel C, Oliveira JP, Vogt L, Waldek S, Hughes DA, Lachmann RH, Terryn W, Hollak CE, Florquin S, van den Bergh Weerman MA, Wanner C, **WEST ML**, Biegstraaten M, Linthorst GE. Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis. *Mol Genet Metab*. 2015;114:242-7.
70. Hollander Z, Dai DL, Putko BN, Yobasundaram H, Wilson-McManus JE, Thompson RB, Khan A, **WEST ML**, McManus BM, Oudit GY. Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease. *European Journal of Heart Failure* 2015;17:291-300. doi: 10.1002/ejhf.230.
71. Beck M, Hughes D, Kampmann C, Larroque S, Mehta A, Pintos-Morell G, Ramaswami U, **WEST M**, Wijatyk A, Giuliani R and the Fabry Outcome Survey Group. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis. *Journal of Inherited Metabolic Disease Reports* 2015;3:21-27. doi: 10.1016/j.ymgmr.2015.02.002.
72. Sirrs S, Bichet D, Iwanochko M, Khan A, Moore D, Oudit G, **WEST M**. Canadian Fabry Disease Treatment Guidelines 2016. <http://www.garrod.ca/wp-content/uploads/FD-Treatment-Guidelines-2016.pdf>
73. Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, **WEST ML**, Wanner C. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. *Kidney International* 2017; 91:284-293.

74. Shen JS, Arning E, **WEST ML**, Day TS, Chen S, Meng XL, Forni S, McNeill N, Goker-Alpan O, Wang X, Ashcraft P, Moore DF, Cheng SH, Schiffmann R, Bottiglieri T. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease. *Hum Mol Genet.* 2017 Feb 2. doi: 10.1093/hmg/ddx032.
75. Huang J, Khan A, Au B, Barber D, López-Vásquez L, Prokopishyn N, Boutin M, Rothe M, Rip J, Abaoui M, Murtaza N, Dworski S, Schambach A, Keating A, **West M**, Klassen J, Turner P, Sirrs S, Rupar CA, Auray-Blais C, Foley R, Medin J. Lentivector iterations and pre-clinical scale-up/toxicity testing: Targeting patient mobilized CD34+ hematopoietic cells for correction of Fabry disease. *Molecular Therapy - Methods & Clinical Development.* 2017. Accepted for publication.

CONTRIBUTED PAPERS IN PUBLISHED CONFERENCE PROCEEDINGS AND ABSTRACTS

1. **WEST ML**, Goldstein MB, Halperin ML. The Urine Anion Gap (UAG) - A clinically useful diagnostic tool. *Clin Invest Med.* 8:A156,1985.
2. Jindal K, **WEST ML**, Bear R, Goldstein M. Benefit of Cyclophosphamide Therapy (CT) in Patients with Membranous Glomerulonephritis (MGN) and Impaired Renal Function. *Kidney Int.* 29:192,1986 and *Clin Invest Med.* 9:A108,1986.
3. **WEST ML**, Zettle RM, Sonnenberg H, Halperin ML. Mechanisms responsible for potassium (k) excretion in adrenalectomized (Adx) rats. *Clin Res.* 34:702A, 1986 and *Clin Invest Med.* 9:A46,1986.
4. Josse RG, Leiter LA, **WEST ML**, Halperin ML. Development of Severe Metabolic Acidosis During Total Fasting Following KCL Administration. *Clin Res.* 34:546A, 1986 and *Clin Invest Med.* 9:A45,1986.
5. Zettle RM, **WEST ML**, Chen CB, Halperin ML. Does the Kidney "Escape" from the Kaliuretic Action of DOCA? *Clin and Invest Med.* 9:A112,1986.
6. Singer GG, Zettle RM, **WEST ML**, Richardson RMA, Marsden P, Josse RG, Halperin ML. Renal Investigation of Low Aldosterone (ALDO) States. *Clin Invest Med.* 9:A46, 1986.
7. **WEST ML**, Chen CB, Singer GG, Richardson RMA, Sonnenberg H, Halperin ML. A Non-invasive Method to Evaluate the Renal Response to Aldosterone (ALDO) In Vivo. *Kidney Int.* 29:208A,1986.
8. Zettle RM, **WEST ML**, Chen CB, Halperin ML. Renal Mechanisms Limiting K Excretion During Hypokalemia Induced by Chronic Administration of Deoxycorticosterone Acetate (DOCA). *Kidney Int.* 31:443A,1986.

9. **WEST ML**, Margolis B, Robinson L, Halperin R, Halperin ML. The Urine Osmolar Gap: A Clinical Clue for Occult Ketoacidosis. *Kidney Int.* 31:224A,1987 and *Clin Invest Med.* 10:B103,1987.
10. Leiter LA, **WEST ML**, Josse RG, Halperin ML. Reduction in NH_4 Excretion by K During Fasting Ketoacidosis. Effect on Acid-Base Balance. *Clin Invest Med.* 10:B67, 1987.
11. **WEST ML**, Halperin ML. Potassium Excretion in Severely Hyperglycemic Patients: A Reversible Diminished Response to Aldosterone. *Clin Invest Med.* 10:B103,1987 and *Kidney Int.* 33:214,1988.
12. The Canadian Glomerulonephritis Study Group (incl **M. WEST**). Initial Observations from the Restricted Protein-Cyclosporine/Placebo Trial in Patients with Primary Glomerulonephritis. *Clin Invest Med.* 11:C84,1988.
13. Jindal KK, **WEST ML**, Bear RA, Goldstein MB. Benefit of Cyclophosphamide Therapy in Patients with Membranous Glomerulonephritis and Impaired Renal Function. *Xth International Congress of Nephrology, London, p.63,1988.*
14. Dyck RF, Asthana S, Kalra J, **WEST ML**, Massey KL. The Modified Urine Osmolar Gap: An Estimate of Urine $[\text{NH}_4^{4+}]$. *Clin Invest Med.* 12:B67,1989
15. Cattran DC, Cole E, Bernstein K, Churchill D, Greenwood C, Lavoie S, Morrin P, Roscoe J, **WEST M**, Whiteside C. A Comparison of the Effects on Renal Function using Angiotensin Converting Enzyme Inhibitors vs. Conventional Antihypertensive Therapy in Patients with Primary Glomerulonephritis. *Clin Invest Med.* 13:B72,1990.
16. Jindal K, **WEST M**, Bear R, Goldstein M. Long-Term Benefits of Therapy with Cyclophosphamide and Prednisone in Patients with Membranous Glomerulonephritis and Impaired Renal Function. *Clin Invest Med.* 13:B73,1990.
17. **WEST ML**, Dyck RF, Cunningham TA. Immunosuppressive Treatment of Severe IgA Nephropathy. *Clin Invest Med.* 13:B81,1990.
18. Cattran DC for the Canadian Glomerulonephritis Study Group (including **M. WEST**). Evaluation of Compliance to Diet and Renal Function Changes in Primary Glomerulonephritis Patients. *Am J Kid Dis.* 15:A4,1990.
19. Shukoor S, Kalra J, Massey KL, **WEST ML**. An Unusual Bladder Calculus Associated with Renal Failure. *Can Congress Lab Med.* A29:75,1990.
20. Jindal K, **WEST M**, Bear R, Goldstein M. Long-Term Benefits of Therapy with Cyclophosphamide and Prednisone in Patients with Membranous Glomerulonephritis and Impaired Renal Function. *J Am Soc Nephrol.* 1:309,1990.

21. MacKay E, **WEST ML**. Neutropenia with Allopurinol Induced Hypersensitivity Reaction (HSR). *Clin Invest Med*. 15:A94,578,1992.
22. **WEST ML**, Jindal KK. Peritonitis Presenting as Acute Catheter Obstruction in Non Continuous Forms of Peritoneal Dialysis. *Clin Invest Med*. 15:A97,595,1992.
23. Hirsch DJ, **WEST ML**, Jindal KK, Cohen AD. Patients Not Offered Dialysis Therapy by a Regional Program. *Clin Invest Med*. 16:B106,662,1993.
24. **WEST ML**, Prabhu U, Gupta R. Antineutrophil Cytoplasmic Antibody Associated Glomerulonephritis in Nova Scotia 1990-91. *Clin Invest Med*. 16:B104,649,1993.
25. **WEST ML**, Trillo A. Kappa Light Chain Deposition Disease Complicated by Hypopituitarism. *Clin Invest Med*. 16:B105,655,1993.
26. Salazar AB, Lawen JG, Al-Khudair W, Gupta R, Bitter-Suermann H, MacDonald AS, McAlister V, **WEST M**, Belitsky P. Fate of Second Kidney Transplants When the First was Lost from Rejection in the First Week. *Clin Invest Med*. 16:B143,884,1993.
27. Sepandj F, Jindal K, **WEST M**, Hirsch D. Economic Appraisal of Maintenance Parenteral Iron Administration in Treatment of Anemia in Chronic Hemodialysis Patients. *J Am Soc Nephrol*. 5:18P,476,1994.
28. **WEST M**, Fraser A, Boss S, Dhar J, Macneil A, Schuberth J. False Elevation of the Serum Creatinine by Ingestion of Model Airplane Fuel. *Clin Invest Med*;18(4):B81, 1995.
29. Keough-Ryan TM, **WEST ML**. Renal Failure Secondary to Procidencia. *Clin Invest Med*. Suppl.20:S43,1997.
30. Panek R, **WEST ML**, Geldenhuys L. Fibronectin Glomerulonephritis Presenting with Rapid Decline in Renal Function and Hypersensitivity Features. *J. Am Soc Nephrol*. 12:120A,2001.
31. Thadhani R, Wolf M, Tonelli M, **WEST ML**, Obrador G. Fabry Disease Patients on Dialysis in the US and Europe: A Comparison Study. *J Am Soc Nephrol* 12:86A,2001.
32. Thadhani R, Wolf M, **WEST ML**, Tonelli M, Obrador G. Patients with Fabry Disease on Dialysis in the United States. *J Am Soc Nephrol*. 12:86A,2001.
33. **WEST ML**, LeMoine K, McKillip R, Harnett J. Renal Transplantation in the Nova Scotia Fabry Disease Kindred. *J Am Soc Nephrol*. 13(Suppl 3): A,2002.
34. **WEST ML**, LeMoine K, Simms C, Dyack S. Cross-Sectional Analysis of Renal Disease

- in the Nova Scotia Fabry Disease Kindred. *J Am Soc Nephrol.* 139Suppl 3):517A,2002.
35. **WEST ML**, Dyack S, Riddell C, LeMoine K, Camfield C, Camfield P. A Nova Scotia Kindred with Fabry Disease. *Amer J Hum Gen.* 71:418,2002.
 36. **WEST M**, Dyack S, Riddell C, LeMoine K, Camfield C, Camfield P. A Nova Scotia kindred with Fabry disease. *Acta Paediatrica.* 19:439S:116,2002.
 37. **WEST M**, LeMoine K, Simms C, Dyack S. Cross-sectional analysis of renal disease in the Nova Scotia Fabry disease kindred. *Acta Paediatrica.* 19:439S:126,2002.
 38. **WEST M**, LeMoine K, McKillup R, Harnett J. Renal transplantation in the Nova Scotia Fabry disease kindred. *Acta Paediatrica.* 19:439S:133,2002.
 39. Thanamayooran S., **WEST ML**, Dyack S, LeMoine K, Riddell C, Simms C. A Fabry disease homozygote in the Nova Scotia Kindred with a classic hemizygote phenotype. *Acta Paediatrica.* 92:443S:108,2003.
 40. **WEST M**, Geldenhuys L and LeMoine K. Response of rapidly progressive Fabry disease nephropathy in a female to enzyme replacement therapy. *Acta Paediatrica.* 95:451S:108, 134,2006.
 41. **WEST, M** and LeMoine K. Effect of changing therapy from agalsidase- β to agalsidase- α in Fabry disease. *Acta Paediatrica.* 95:451S:108,136,2006.
 42. Fogo A, Oliveira J-P, Waldek S and Warnock D. on behalf of the International Fabry Kidney Biopsy Working Group (IFBWG) (**incl. M. WEST**) Developing a Chronicity Index for Kidney Involvement in Fabry Disease. *J Am Soc Nephrol.* 17:626A,2006.
 43. Cybulla M, Schwarting A, Barbey F, Feriozzi S, Sunder-Plasmann G, and **WEST M**. Proteinuria in Fabry Nephropathy during Enzyme Replacement Therapy (ERT). *J Am Soc Nephrol.* 17:625A,2006.
 44. **WEST M**, Nicholls K, Clarke J, Steiner R, Mehta A, Schiffmann R. Effects of Long-term Agalsidase-alfa (Replagal)[®] Therapy on Renal Function in Male Fabry Patients. *J Am Soc Nephrol* 17:378A, 2006.
 45. Constantine C. and **WEST M**. Calciphylaxis Refractory to Sodium Thiosulfate in a Dialysis Patient: Improvement with Intravenous Pamidronate. *J Am Soc Nephrol.* 17: 896A,2006.
 48. Clarke JT, **WEST ML**, Bultas J, Schiffmann R. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. *Molecular Genetics and Metabolism.* 92:S25,2007.

49. **WEST M**, LeMoine K. Withdrawal of Enzyme Replacement Therapy in Fabry Disease: Indirect Evidence of Benefit? *Molecular Genetics and Metabolism*. 92:S32,2007.
50. Tennankore KK, LeMoine K, **WEST ML**. Withdrawal of Enzyme Replacement Therapy in Fabry Disease – Indirect Evidence of Treatment Benefit? *J Am Soc Nephrol*. 18:135A, 2007.
51. Sunder-Plassmann G, Deegan P, Nicholls K, Feriozzi S, Schwarting A, Cybulla M, **WEST M**, Mehta A, FOS Investigators. Predictive performance of GFR estimates in 158 patients with Fabry disease. *J Am Soc Nephrol*. 18:837A,2007.
52. **WEST M**, Cybulla M, Feriozzi S, Schwarting A, Sunder-Plassmann G. Effect of Agalsidase Alfa on the Decline in Renal Function in Fabry Nephropathy. *J Am Soc Nephrol*. 18:103A,2007.
53. Sirrs SM, Casey R, Clarke JTR, Bichet DG, LeMoine K, and **WEST ML**. Baseline characteristics of patients in the Canadian Fabry Disease Initiative. *J Inherit Metab Dis*. 31(Supplement 1):120,2008.
54. Sirrs SM, **WEST ML**, Flowerdew G, LeMoine K, Bichet D, Casey R, Clarke J, Sirrs S, Auray-Blais C. The Canadian Fabry Disease Initiative: A Randomized Controlled Trial of Agalsidase therapy in Fabry disease. *Mol Genet Metab*. 98:Abstract 105,2009.
55. **WEST M**, LeMoine K, Bichet D, Clarke J, Casey R, Sirrs S, Auray-Blais C. A randomized controlled trial of enzyme replacement therapy in Fabry nephropathy: the Canadian Fabry Disease Initiative at year two. *J Am Soc Nephrol* 20:747A, 2009.
56. Feriozzi S, **WEST M**, Cybulla M, Nicholls K, Torras J, Sunder-Plassmann G. Effects of more than 5 years of enzyme replacement therapy with agalsidase alfa on renal function in patients with Fabry disease. *J Am Soc Nephrol*. 20:414A,2009.
57. Feriozzi S, Cybulla M, **WEST M**, Nicholls K, Torres J, Sunder-Plassmann G. Low-Grade Proteinuria Is Associated with Progression of Fabry Nephropathy after More Than 5 Years of Enzyme Replacement Therapy. *J Am Soc Nephrol*. 20:964A,2009.
58. **WEST M**, LeMoine K, Bichet D, Clarke J, Casey R, Sirrs S, Auray-Blais C, Sinasac D, Flowerdew G. A Randomized Controlled Trial of Enzyme Replacement Therapy in Fabry Disease: The Canadian Fabry Disease Initiative at Year Three. *Mol Genet Metab*. 99:S39, 2010.
59. Waldek S, Giannini E, Mehta A, Hilz M, Beck M, Bichet D, Brady R, **WEST M**, Germain D, Wanner C, Clarke J, Warnock D, Linhart A. A validated disease severity scoring system for Fabry disease. *Mol Genet Metab*. 99:S37,2010.
60. Sirrs S, Clarke J, Bichet D, Casey R, LeMoine K, Flowerdew G, **WEST M**. Agalsidase

- alfa and agalsidase beta have similar effects on Fabry outcomes - results from the Canadian Fabry Disease Initiative. *J Inherit Metab Dis.* 33(Supplement 1):S126,2010.
61. **WEST ML.** ARBs/ACE inhibitors in Fabry disease: rescue or peril? *International Journal of Clinical Pharmacology and Therapeutics.* 48(Supplement 1):S22-S23,2010.
62. **WEST M,** Flowerdew G, LeMoine K, Bichet D, Casey R, Clarke J, Sirrs S, Auray-Blais C. The Canadian Fabry disease Initiative: a randomized controlled trial of agalsidase therapy in Fabry nephropathy. *International Journal of Clinical Pharmacology and Therapeutics.* 48(Supplement 1):S51,2010.
63. **WEST M,** LeMoine K, Bichet D, Clarke J, Casey R, Sirrs S, Auray-Blais C, Sinasac D, Flowerdew G. A Randomized Controlled Trial of Enzyme Replacement Therapy in Fabry Disease: The Canadian Fabry Disease Initiative at Year Three. *J Am Soc Nephrol.* 21:138A,2010.
64. **WEST M,** Bichet D, Casey R, Clarke J, Sirrs S, LeMoine K, Auray-Blais C. Influence of Anti-agalsidase Antibodies on Clinical Outcomes in the Canadian Fabry Disease Initiative Study. *J Am Soc Nephrol.* 21:140A,2010.
64. **WEST M,** Schiffmann R, Mehta A, Amato D, Nair N, Zahrieh D, Huertas P. Enzyme Replacement Therapy With Agalsidase Alfa (Replagal) Slows Progression Of Renal Dysfunction In Male Patients With Fabry Disease: Results Of An Integrated Analysis. *Nephrology Dialysis Transplant Plus.* 4(Suppl 2),2011. :doi: 10.1093/ndtplus/4.s2.5.
65. **WEST M,** Flowerdew G, LeMoine K, Bichet D, Casey R, Clarke J, Sirrs S, Auray-Blais C. Agalsidase Alfa and Agalsidase beta Have Similar Effects on Outcomes in Fabry Disease-results from the Canadian Fabry Disease Initiative, *Molecular Genetics and Metabolism.* 102:S46,2011.
65. Schiffmann R, Blankenship D, Nicholls K, Mehta A, Clarke JTR, Steiner R, Beck M, Barshop B, Rhead W, **WEST M,** Martin R, Amato D, Nair N, Huertas P. Are globotriaosylceramide concentrations useful as surrogate markers to evaluate therapy for Fabry disease? *J Inherit Metab Dis.* 34(Supplement 3):S186,2011.
66. Sirrs S, Flowerdew G, Whyte J, Lemoine K, Bichet DG, Casey R, Clarke JTR, and **WEST ML** on behalf of the CFDI Investigators. Rate of decline of GFR in patients with Fabry disease (FD): Prospective natural history data from the Canadian Fabry Disease Initiative (CFDI). *J Inherit Metab Dis.* 34(Supplement 3):S228,2011.
67. **WEST M,** Bichet D, Casey R, Clarke J, Sirrs S, Flowerdew G, LeMoine K for the CFDI Investigators. Prospective Results of Switching Enzyme Replacement Therapy from Agalsidase beta to Agalsidase alfa in the Canadian Fabry Disease Initiative Study. *Mol Genet Metab.* 105:S64-S65,2012.

68. **WEST M**, Bichet D, Casey R, Clarke J, Sirrs S, LeMoine K, Auray-Blais C. Influence of Anti-Agalsidase Antibodies on Clinical Outcomes in the Canadian Fabry Disease Initiative Study. *Clinical Therapeutics*. 34(4):e25,2012.
69. Brinks V, Richards S, Ruiz J, Aerts H, von Landenberg P, **WEST M**, Breunig F, Wanner C, Wadhwa M. Fabry Disease Antibody Standardization Initiative (FASI). *Molecular Genetics and Metabolism*. 105:S22-S23,2012.
70. Sirrs S, LeMoine K, Bichet DG, Casey R, Clarke JTR, **WEST ML**. Rate of change of GFR and LV mass in Fabry disease: Targets for therapeutic goals from the Canadian Fabry Disease Initiative (CFDI). *J Inherit Metab Dis*. 35(Suppl1):S92,2012.
71. Cybulla M, **WEST M**, Nicholls K, Torras J, Sunder-Plassmann G, Feriozzi S. Effectiveness and Safety of Enzyme Replacement Therapy (ERT) in a Cohort of Kidney Transplant Recipients with Fabry Disease. *J Am Soc Nephrol*. 23:867A,2012.
72. Mauer M, Whitley CB, Svarstad E, Tøndel C, Gubler M-C, **WEST ML**, Najafian B. Structural-Functional Relationships of Fabry Nephropathy. *J Am Soc Nephrol*. 23:732A, 2012.
73. Najafian B, Whitley C, Thurberg BL, Svarstad E, Tøndel C, Gubler MC, **WEST ML**, Mauer M. Renal Structural-Functional Relationship Studies Suggest that Podocyte GL-3 Accumulation Predicts Urine Protein Creatinine Ratio in Patients with Fabry Disease (FD). *Molecular Genetics and Metabolism*. 108:S68,2013.
74. **WEST M**, Bichet D, Casey R, Clarke J, Sirrs S, LeMoine K, Doucette S for the CFDI Investigators. Benefit of Enzyme Replacement Therapy in Fabry Disease: Comparison of Outcomes in the Canadian Fabry Disease Initiative Study. *Molecular Genetics and Metabolism*. 108:S97,2013.
75. **WEST M**, Bichet D, Casey R, Clarke J, Sirrs S, Auray-Blais C, Aerts J, LeMoine K, Doucette S for the CFDI Investigators. Clinical Effects of Neutralizing Anti-agalsidase Antibodies in Patients Receiving Enzyme Replacement Therapy in the Canadian Fabry Disease Initiative Study. *Molecular Genetics and Metabolism*. 108:S97,2013.
76. Auray-Blais C, Boutin M, Lavoie P, Casey R, Clarke JTR, Foley SR, Keating A, Khan A, **WEST ML**, Medin J. Gene therapy for Fabry disease patients: The importance of efficient biomarker monitoring. *Molecular Genetics and Metabolism*. 108:S21,2013.
77. Van der Tol L, Biegstraaten M, Florquin S, Vogt L, van den Bergh Weerman MA, Hollak CEM, Hughes DA, Lachmann RH, Oliveira JP Ortiz AA, Svarstad E, Terry W, Tondel C, Waldek S, Wanner C, **WEST ML**, Linthorst GE. Consensus Recommendation on Fabry Disease Diagnosis in Adult Patients with Kidney Disease. *Molecular Genetics and Metabolism*. 111:S108,2014.

78. Smid B, van der Tol L, Cecchi F, Elliott P, Hughes D, Linthorst G, Timmermans J, Weidemann F, **WEST M**, Biegstraaten M, LeKanne Dit Deprez R, Florquin S, Postema P, van der Wal A, van den Bergh Weerman M, Hollak C. Consensus Recommendation on Fabry Disease Diagnosis in Adult Patients with Left Ventricular Hypertrophy. *Molecular Genetics and Metabolism*. 111:S99,2014.
79. Arning E, Shen J-S, LeMoine K, Schiffmann R, **WEST M**, Bottiglieri T. Tetrahydrobiopterin in Fabry Disease. *Molecular Genetics and Metabolism*. 111:S20, 2014.
80. Dyack S, **WEST M**, Sirrs S for the CFDI Investigators. Pediatric Fabry Disease in Canada: 5 year data from the CFDI. *Molecular Genetics and Metabolism*. 111:S39,2014.
81. Rupar T, Khan A, Au BC, Tailor C, Rothe M, Bischof D, Sirrs S, Auray-Blais C, Prokopishyn N, O'Hoski P, Benabid R, Viswanathan S, Morel C, Raiman J, Schambach A, **WEST M**, Keating A, Cornetta K, Foley R, Medin JA. Towards a clinical trial of lentivirus-mediated gene therapy for Fabry disease: In vitro patient cell mobilization and transduction outcomes. *Clinical Biochemistry* 47(15):151,2014.
82. **WEST ML**, Bichet DG, Khan A, Clarke JT, Sirrs S, Doucette S, Auray-Blais C, LeMoine K on behalf of the CFDI Investigators. Outcomes of Patients 65 and Older in the Canadian Fabry Disease Initiative Study. *J Am Soc Nephrol* 26, 2015:394A.
83. Najafian B, Tøndel C, Svarstad E, **WEST ML**, Mauer M. Podocyte Globotriaosylceramide (GL3) Accumulation in Fabry Disease Is Influenced by Age and Genotype. *J Am Soc Nephrol* 26:393A,2015.
84. Beck M, Hughes D, Kampmann C, Mehta A, Pintos-Morell G, Ramaswami U, **WEST ML**, Wijatyk A, Giugliani R. The long-term effectiveness of agalsidase alfa in Fabry disease: a Fabry Outcome Survey analysis. *Molecular Genetics and Metabolism*. 114:S23, 2015. doi:10.1016/j.ymgme.2014.12.025
85. Beck M, Hughes D, Kampmann C, Bizjajeva S, Pintos-Morell G, Ramaswami U, **WEST M**, Giugliani R. Long-term outcomes with agalsidase alfa enzyme replacement therapy: analysis using deconstructed composite events. *Molecular Genetics and Metabolism*. 117:S25,2016.
86. Ramaswami U, Beck M, Hughes D, Kampmann C, Bizjajeva S, Pintos-Morell G, **WEST M**, Niu D-M, Nicholls K, Giugliani R. Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry Outcome Survey analysis. *Molecular Genetics and Metabolism*.117:S98,2016.
87. Sirrs S, Bichet D, Casey R, Clarke JTF, Iwanochko M, Khan A, Auray-Blais C, Doucette S, LeMoine K, **WEST ML** for the CFDI Investigators Group. Canadian Fabry Disease Initiative Study (CFDI): 8 year Outcomes of Enzyme Replacement Therapy (ERT). *J*

Inherited Metabolic Disease. 39(Suppl 1):S24,2016.

88. Morel CF, Bichet D, Casey R, Clarke JTF, Iwanochko M, Khan A, Sirrs S, Auray-Blais C, Doucette S, LeMoine K, **WEST ML**, for the CFDI Investigators Group. Switch of Enzyme Replacement Therapy (ERT) in the Canadian Fabry Disease Initiative Study (CFDI). J Inherited Metabolic Disease. 39(Suppl 1):S25,2016.
89. Sunder-Plassmann G, Cybulla M, Feriozzi S, Neumann P, Nicholls K, **WEST M**, Torras J, Gurevich A. Literature Review of the Prevalence of Fabry Disease in Dialysis, Kidney Transplant And Chronic Kidney Disease Populations. J Inherited Metabolic Disease. 39(Suppl 1):S25,2016.
90. Shen J-S, Arning E, **WEST ML**, Day TS, Cheng SH, Schiffmann R, Bottiglieri T. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease. Molecular Genetics and Metabolism. 120:S123,2016.

BOOK REVIEWS

1. The Renal Biopsy. Annals Royal College of Physicians and Surgeons of Canada 1998

INVITED LECTURES AND INVITED PRESENTATIONS

1. Renal Transplantation in 1986. Kidney Foundation of Canada, Saskatoon and District Chapter. Saskatoon, Sask. November 20, 1986.
2. Renal Disease and Pregnancy. Department of Obstetrics & Gynecology. University Hospital, Saskatoon, Sask. January 6, 1987.
3. CVP Lines. Nursing In-service, University Hospital, Saskatoon, Sask. March 4 and 25, 1987.
4. Overview of Clinical Transplantation. Nursing Education. University Hospital, Saskatoon, Sask. March 17, 1987.
5. Fluid and Electrolyte Problems; Interstitial Nephritis Workshops. CME. Nephrology-Urology Update, Saskatoon, Sask. May 22-23, 1987
6. Hematuria. Pediatric Rounds. University Hospital, Saskatoon, January 10, 1988. Arterial Blood Gases. CNE. Workshop. Tisdale Union Hospital Nurses, Tisdale, Saskatchewan. January 13, 1988.
7. Arterial Blood Gases. CME. Workshop. Carrot River District Medical Society, Tisdale, Saskatchewan. January 13, 1988.
8. Update on Hemodialysis Kidney Foundation of Canada, Saskatoon and District Chapter. February 15, 1988.

9. Renal Disease and Pregnancy. Department of Obstetrics & Gynecology, University Hospital, Saskatoon, Sask. April 26, 1988.
10. Acute Renal Failure. Critical Care Nursing Course. University Hospital, Saskatoon, Sask. April 29, 1988 and June 21, 1988.
11. Acute Renal Failure. Canadian Association of Critical Care Nurses, Saskatoon Branch. Saskatoon, Sask. September 21, 1988.
12. Diagnosis and Treatment of Methanol Overdose. Ophthalmology Rounds. University Hospital, Saskatoon, Sask. February 8, 1989.
13. Complications of Hemodialysis. Nursing In-service, University Hospital, Saskatoon, Sask. March 14, 1989.
14. Diagnostic Imaging in Renal Transplantation. Saskatchewan Association of Diagnostic Medical Sonographers and Saskatchewan Association of Medical Radiation Technologists Annual Meeting, Regina, Sask. April 29, 1989.
15. Urea Kinetic Modeling in Hemodialysis. Nursing In-service, University Hospital, Saskatoon, Sask. May 9, 1989.
16. Visiting Professor, Department of Medicine, Dalhousie University, Halifax, Nova Scotia: The TTKG: A New Approach to Potassium Disorders - June 1, 1989. Treatment of Membranous Glomerulonephritis - June 2, 1989.
17. Acid-Base and Electrolyte Disorders in Dialysis Patients. Nursing In-service, University Hospital, Saskatoon, Sask, September 12, 1989.
18. The Role of Diet in Delaying Renal Failure. Saskatchewan Dietetic Association Conference, Saskatoon, Sask. November 6, 1989.
19. Current Nephrology Research. Kidney Foundation of Canada, Saskatoon and District Chapter. Saskatoon, Sask. November 27, 1989.
20. Assessment of the Hemodialysis Patient. Nursing In-Service, University Hospital, Saskatoon, Sask. December 7, 1989.
21. Drugs and Dialysis. Nursing In-Service. University Hospital, Saskatoon, Sask. March 15, 1990.
22. Acute Renal Failure. CME. Nephrology-Urology Update, St. Paul's Hospital, Saskatoon, Sask. May 4, 1990.
23. Rationalization of Saskatoon Medical Services. Interview CBC AM Radio,

- Saskatoon, Sask. Morning Edition. August 16, 1990.
24. A Case of Hyperkalemia. Nephrology Seminar, Department of Medicine, Saint John Regional Hospital, Saint John, N.B. October 30, 1990.
 25. Approach to the Nephrotic Syndrome. Medical Grand Rounds, Department of Medicine, Saint John Regional Hospital, Saint John, N.B. October 30, 1990.
 26. Studies of Renal Tubular Responsiveness to Exogenous Mineralocorticoids. Research Day, Department of Medicine, Dalhousie University, Halifax, N.S. November 28, 1990.
 27. Proteinuria. CME Update on Renal Disease for Family Physicians, Dalhousie University, Halifax, N.S. January 18, 1991.
 28. Diabetic Kidney Disease. Kidney Foundation of Canada, Amherst Chapter and Canadian Diabetes Association, Amherst Chapter, Amherst, N.S. May 16, 1991.
 29. Review of Laboratory Tests Relevant to Nephrology. Nursing In-Service, Victoria General Hospital, Halifax, N.S. June 13, 1991.
 30. Treatment of Hypertension in Diabetes Mellitus. CME, Brudenell River Resort, P.E.I. September 16, 1991.
 31. Treatment of Hyperkalemia. Emergency Rounds, Victoria General Hospital, Halifax, N.S. November 12, 1991.
 32. Peritoneal Dialysis Adequacy Study and Medical Research Funding. Kidney Foundation of Canada, Nova Scotia Branch, Dartmouth, N.S. January 11, 1992.
 33. Peritoneal Dialysis Adequacy Study and Medical Research Funding in Canada. Kidney Foundation of Canada, Marine Drive Chapter, Lake Charlotte, N.S. April 29, 1992.
 34. Nephrology Research in Nova Scotia. Radio Interview CFRB, Halifax, N.S. March 28, 1992.
 35. Erythropoietin Update. Patient Education Day Kidney Foundation of Canada, Nova Scotia Branch, Halifax, N.S. April 4, 1992.
 36. Peritoneal Dialysis Adequacy Study. Kidney Foundation of Canada, Lunenburg Chapter, Bridgewater, N.S. April 8, 1992.
 37. Patients Entering the Cadaver Wait List. Transplant Atlantic Meeting. Halifax, N.S. April 15, 1992.

38. ANCA Positive Glomerulonephritis. Medical Grand Rounds, Department of Medicine, Saint John Regional Hospital, Saint John, N.B. September 22, 1992.
39. Coding Renal Procedures and Diagnoses. Inservice Medical Records, Victoria General Hospital, Halifax, N.S. December 2, 1992.
40. Organ and Tissue Donation in Nova Scotia Medical Grand Rounds, Aberdeen Hospital, New Glasgow, NS., 1993. March 17, 1993.
41. Erythropoietin Update. Kidney Foundation of Canada, Cape Breton Chapter. Patient Education Day. Sydney, N.S. May 1, 1993.
42. ANCA Associated Glomerulonephritis. Symposium for General Internists, Canadian Society of Internal Medicine, Digby, NS, June 4, 1993.
43. Diuretics. Clinical Assistants' Lecture, Victoria General Hospital, Halifax, N.S. June 8, 1993.
44. Canadian Society of Nephrology Challenging Consult Series: A Patient with Severe Metabolic Acidosis, Hyperglycemia, Hypernatremia and Hyperkalemia. Royal College of Physicians and Surgeons Annual Meeting, Toronto, Ontario. September 17, 1994
45. Diabetic Nephropathy. Kidney Foundation of Canada, Nova Scotia Branch, Patient Education Day. Sydney, NS. April 22, 1995.
46. Predialysis Management of Chronic Renal Failure. Queen Elizabeth II Health Sciences Centre & Provincial Dialysis Program. Halifax, NS. September 22, 1995.
47. CNE Review of Renal Anatomy and Physiology, Nephrology Nursing Certification Exam Review, Queen Elizabeth II Health Sciences Centre, Halifax, NS, March 5, 1996.
48. Epidemiology of Primary Glomerulonephritis in Canada. 2nd Annual Workshop, Canadian Society of Nephrology, CME, Halifax, NS, September 26, 1996.
49. Anemia and Erythropoietin. Continuing Nursing Education, Peritoneal Dialysis Seminar, Queen Elizabeth II Health Sciences Centre, Halifax, NS, October 4, 1996.
50. Internet Resources For Nephrologists, Bits and Bytes Symposium, Canadian Society of Nephrology. RCPSC Annual Meeting, Vancouver, BC, September 28, 1997.
51. Anticoagulation and Hemodialysis. Hemodialysis Workshop, Queen Elizabeth II Health Sciences Centre, Halifax, N.S., May 26, 1998.

52. Approach to the Patient with an Elevated Serum Creatinine. Continuing Medical Education Videoconference, Dalhousie University Faculty of Medicine, November 5, 1998.
53. Investigation of Elevated Serum Creatinine. Continuing Medical Education, Dalhousie University Faculty of Medicine, Queen Elizabeth II Health Sciences Centre, Halifax N.S., November 12, 1998.
54. ANCA-associated Renal Disease. Medical Grand Rounds, Saint John Regional Hospital, Saint John, N.B., November 17, 1998.
55. A Patient with Hyperkalemia. Noon Teaching Rounds, Saint John Regional Hospital, Saint John, N.B., November 17, 1998.
56. Managing Acute Renal Failure. Continuing Medical Education, Dalhousie University Faculty of Medicine, QEII Health Sciences Centre, Halifax NS, January 9, 1999
57. Investigation of a Patient with an Elevated Serum Creatinine. Continuing Medical Education, Dalhousie University, Aberdeen Hospital, New Glasgow NS, March 10, 1999
58. Approach to the Patient with an Elevated Serum Creatinine. Continuing Medical Education Videoconference, Dalhousie University Faculty of Medicine, September 29, 1999.
59. Approach to the Patient with an Elevated Serum Creatinine. Continuing Medical Education, Dalhousie University, Wolfville, NS, October 7, 1999
60. Renal Failure in the Ambulatory Patient. 73rd Annual Dalhousie Refresher Course, World Trade and Convention Centre, Halifax NS, November 26, 1999
61. Hypercalcemia and Renal Failure. Clinicopathologic Conference, Medical Grand Rounds, Department of Medicine, Dalhousie University, Halifax NS, January 18, 2000
62. Fabry Disease: the Promise of Enzyme Replacement Therapy. Medical Grand Rounds, Department of Medicine, Dalhousie University, Halifax NS, March 6, 2001
63. Enzyme Replacement Therapy. Nova Scotia Society of Internal Medicine Annual Meeting, Blomidon Inn, Wolfville, NS, July 28, 2001-08-08
64. Where Do Angiotensin II Receptor Blockers in Type II Diabetics Fit In? ARB's vs ACEi in Type II Diabetics, GP Journal Club, Halifax, NS, September 10, 2001

65. Management of the Patient with Chronic Renal Failure. Continuing Medical Education, Dalhousie University, Highland View Regional Hospital, Amherst, NS, November 8, 2001
66. Anticipation and Management of Renal Disease in the Diabetic 75th Annual Dalhousie Refresher Course, Continuing Medical Education, Dalhousie University, Halifax, NS, December 6, 2001
67. HUS in Pregnancy, Obstetrics and Gynecology Grand Rounds, IWK-Grace Health Centre, Halifax, NS, December 12, 2001
68. Management of a Patient with Elevated Serum Creatinine, Continuing Medical Education, Dalhousie University, Middleton, NS, January 17, 2002
69. Update on Fabry Disease and Enzyme Replacement Therapy, Chester, NS, February 11, 2002
70. Medication Use in Chronic Renal Failure, 28th Annual February Refresher Course – Therapeutics, Continuing Medical Education, Dalhousie University, Halifax, NS, February 22, 2002
71. Fabry Disease, National Meeting, Genzyme Canada Inc., Quebec City, Quebec, February 27, 2002
72. LMCC Nephrology Review Lecture, Med IV, Dalhousie University, April 3, 2002
73. Management of the Patient with an Elevated Serum Creatinine. Dalhousie CME Videoconference. October 24, 2002.
74. Experience with Treatment of Fabry Disease in Nova Scotia, Canadian LSD Club Meeting, Vancouver, BC, Nov 16, 2002.
75. Fabry Disease, Continuing Nurse Education, QE II HSC, Halifax, NS February 11, 2003
76. Fabry Disease, Division of Nephrology, Department of Medicine, University Hospital Network, Toronto, ON, February 13, 2003.
77. Fabry Disease Screening in Nova Scotia. University of Toronto, Toronto, ON, February 12, 2003.
78. The Role of Enzyme Replacement in Fabry Renal Disease. 12th Congress Argentina de Nefrologia, San Miguel de Tucuman, Argentina, April 3, 2003
79. Update on Fabry Disease and Enzyme Replacement Therapy, Public Information

- Meeting, Antigonish, NS May 10, 2003.
80. Acute Renal Failure. Department of Medicine, Dartmouth General Hospital, Dartmouth, NS May 7, 2003
 81. Urinalysis: What to look for. Continuing Nursing Education QE II Health Sciences Centre, Halifax NS May 12, 2003
 82. The Nova Scotia Fabry Disease Kindred. Workshop on Fabry Disease, Palma de Mallorca, Spain Oct. 11, 2003.
 83. The Pulmonary Renal Syndrome. Medical Grand Rounds, Department of Medicine, Dalhousie University, Halifax NS, Oct. 14, 2003.
 84. The Nova Scotia Fabry Disease Kindred. Research Seminar. Division of Hepatology and Gastroenterology. Yale University School of Medicine, New Haven Conn, USA. Oct. 21, 2003.
 85. When to Start ERT for Fabry Disease – NS Clinical Treatment Guidelines. Fabry Society of Canada Patient Meeting, Lunenburg Arms Hotel, Lunenburg, N S, December 1, 2003.
 86. Clinical and Laboratory Skills in Renal Disease. CME “Medicine Matters” Principles and Practice of Medicine, Department of Medicine, Dalhousie University, Halifax, NS. Nov. 28, 2003.
 87. Update on Enzyme Replacement Therapy for Fabry Disease, Public Information Meeting, Lunenburg, NS. Dec. 1, 2003.
 88. Fabry Disease. CBC Information Morning, Telephone Interview, Halifax, NS. February 12, 2004.
 89. Fabry Disease. CBC Television on camera interview, Halifax, NS. February 12, 2004.
 90. Kidney Foundation of Canada: Selective Memories. Kidney Foundation of Canada NS Branch Board Meeting, Halifax, NS. May 8, 2004.
 91. Satellite Hemodialysis. Therapeutics, The 30th Annual Dalhousie February Refresher, The Westin Nova Scotian Hotel, Halifax, NS. May 11, 2004.
 92. The Nova Scotia Fabry Disease Kindred. TKT Canadian Symposium on Fabry Disease, Toronto ON. May 27, 2004.
 93. Enzyme Replacement Therapy for Fabry Disease in Nova Scotia: a Three Year

- Experience. Canadian Society of Nephrology Annual Meeting Toronto ON. May 29, 2004.
94. Fabry Disease. CNE, QE II Health Sciences Centre, Halifax, NS. July 14, 2004.
 95. Fabry Disease: Fabrazyme Phase IV Study Results. Canadian LSD Club Meeting. The Fairmont Royal York Hotel, Toronto, ON. October 26, 2004
 96. Long-term Replagal™ Therapy: Renal Effects. Fabry Disease: The World-wide Experience with Replagal™ (agalsidase alfa). Fairmont Royal York Hotel, Toronto, ON. October 28, 2004.
 97. Funding for Enzyme Replacement therapy for Fabry Disease. CTV news interview, Halifax NS. March 28, 2005.
 98. Funding for Enzyme Replacement therapy for Fabry Disease. CBC Halifax Radio Information Morning interview, Halifax NS. April 26, 2005.
 99. Fabry Disease Clinic. CNE, QE II Health Sciences Centre, Halifax, NS. April 11, 2005.
 100. Fabry Disease in Nova Scotia. Kidney Foundation of Canada Nova Scotia Branch Annual General Meeting. Halifax, NS. May 14, 2005.
 101. Fabry Disease and Reimbursement in Nova Scotia. Public Information Meeting, Mahone Bay, NS. June 21, 2005.
 102. Enzyme Replacement Therapy for Fabry Disease in Canada. Interview: Shawna Richer, The Globe and Mail newspaper, Halifax NS. July 26, 2005.
 103. Reimbursement of Enzyme Replacement Therapy for Fabry Disease in Nova Scotia. Interview: CTV TV news, Halifax NS. Aug. 22, 2005.
 104. Replagal Use in Canada for Fabry Disease. Interview: Jeff Crazner, The Boston Globe newspaper. Sept.13, 2005.
 105. Update on Renal Disease, Advances in the Treatment of Fabry Disease Meeting, Toronto ON. Sept. 17-8, 2005
 106. Fabrazyme use in Canada for Fabry Disease. Interview: Steve Heuser, The Boston Globe newspaper. Oct. 11, 2005.
 107. Fabry Disease: a Rare Condition with Uncommon Costs. CANNT Annual Meeting, Halifax, NS. Oct. 15, 2005.

108. Funding of Enzyme Replacement Therapy for Fabry disease in Nova Scotia. Interview: Michele Mischler, Global television news, Halifax NS. Oct. 24, 2005.
109. Debate: Con-Enzyme Replacement Therapy for Fabry's Disease: Money for Nothing? Canadian Society of Nephrology in America, Philadelphia PA, USA. Nov. 9, 2005.
110. Fabry Disease: Update in 2005. Division of Nephrology, Department of Medicine, Dr. Georges Dumont Hospital, Moncton, NB. Nov. 23, 2005.
111. Fabry Nephropathy: New Skills for the Nephrologist. City Wide Nephrology Rounds. Toronto Health Sciences Network, University of Toronto, Toronto, ON. Feb. 22, 2006.
112. Neurologic Complications of Renal Disease. Division of Neurology Academic Half Day QE II Health Sciences Centre Halifax, NS. May 10, 2006.
113. Fabry Nephropathy and Enzyme Replacement Therapy: Unrealized Potential. Annual Meeting. Garrrod Association of Canada, Halifax NS. May 11, 2006.
114. Canadian Fabry Disease Initiative. Canadian Fabry Association Annual Meeting, Halifax NS. May 12, 2006.
115. Fabry Disease-Patient Self Management. Canadian Fabry Association Annual Meeting, Halifax NS. May 12, 2006.
116. Enzyme Replacement Therapy for Fabry Disease. Canadian Fabry Association Annual Meeting, Halifax NS. May 12, 2006.
117. Canadian Fabry Disease Initiative Study. Canadian Fabry Association Annual Meeting, Halifax NS. May 12, 2006.
118. Fabry Disease and ERT in Canada. Interview: The Globe and Mail, May 12, 2006.
119. Fabry Disease and ERT in Canada. Interview: James Keller Canadian Press, Halifax NS. May 13, 2006.
120. Fabry Disease and ERT in Canada. Interview CTV Chantel Jones, Halifax NS. May 14, 2006.
121. Fabry Disease and ERT in Canada. Interview CBC Radio 1 Information Morning. Don Connolly Halifax NS. May 15, 2006.
122. Fabry Disease and ERT in Canada. Chronicle Herald Interview: John Gillis, Halifax NS. May 17, 2006.

123. Fabry Nephropathy: New Skills for the Nephrologist, Nephrology rounds, Providence Health Centre, St. Paul's Hospital, Vancouver BC. Oct. 21, 2006.
124. Fabry Nephropathy: Management for the Non-nephrologist. Advances in the Treatment of Fabry Disease, Vancouver BC. Oct. 21, 2006.
125. Clinical & Scientific Rationale for Early ERT in Fabry Disease. Workshop on Fabry Disease. Budapest, Hungary. Nov. 11, 2006.
126. Renal Working Group Report. 5th FOS Investigator Meeting, Frankfurt Germany. Jan. 27, 2007.
127. The Facts on Fabry Disease, CME Lunenburg NS. Mar 21, 2007
128. Fabry Disease: what every nephrologist needs to know. 10th Annual Nephrology New Brunswick Forum, St Andrews, NB. May 12, 2007.
129. Chronic Kidney Disease: Before Therapy. 10th Annual Nephrology New Brunswick Forum, St Andrews, NB. May 12, 2007.
130. Nephrogenic Systemic Fibrosis. Medical Grand Rounds, Department of Medicine, Dalhousie University, Halifax NS. Sept. 4, 2007.
131. Fabry Disease: Is treatment effective? Conference on Prevention of Renal Failure. Toronto ON. Sept. 29, 2007.
132. The Canadian Fabry Disease Initiative: a new paradigm for drug evaluation in Canada. Pediatric Grand Rounds, University of Sherbrooke, Sherbrooke, QC. Mar. 12, 2008.
133. The Canadian Fabry Disease Initiative Annual Report. CIHR International Oversight Committee Meeting, CFDI study, Toronto ON. Mar. 16, 2008.
134. Transition in End Stage Kidney Disease. Transition of Youth From Pediatric to Adult Health Care. Dalhousie University, Halifax, NS. April 5, 2008.
135. Fabry Disease in Nova Scotia. Pathology Grand Rounds, QE II Health Sciences Centre, Halifax NS. April 9, 2008.
136. Management of the Patient with an Elevated Serum Creatinine, Continuing Medical Education Videoconference, Dalhousie University, Halifax, NS. April 15, 2008.
137. Management of Fabry Nephropathy, LSD Club Meeting, Toronto ON. May 1, 2008.

138. The Canadian Fabry Disease Initiative Study: What are we going to learn? Advances in the Treatment of Lysosomal Storage Disorders Conference, Halifax NS. June 6-8, 2008.
139. Clinicopathologic Conference Case Presentation: a patient with chest pain. Advances in the Treatment of Lysosomal Storage Disorders Conference, Halifax NS. June 6-8, 2008.
140. Fabry Disease: an animal of a different colour. Genetics Rounds, Department of Medical Genetics, University of Calgary, Calgary AB. Oct. 8, 2008.
141. Treatment of Fabry Disease. Medical Genetics Resident Teaching Round. University of Calgary, Calgary, AB. Oct. 8, 2008
142. The Canadian Fabry Disease Initiative Study-a Review. Canadian Fabry Association Meeting, Oak Island Inn, Martins River, NS. Nov. 8, 2008.
143. A Review of Therapy in Fabry Disease. Canadian Fabry Association Meeting, Oak Island Inn, Martins River, NS. Nov. 8, 2008.
144. Fabry Disease-a clinical review. Amicus Symposium. American Society of Human Genetics Annual Meeting, Philadelphia, PA, USA. Nov 12, 2008.
145. Fabry Disease-what every physician needs to know. Annual Dalhousie University Refresher CME Meeting, Halifax NS. Dec. 4, 2008.
146. Enzyme Replacement Therapy in Heterozygotes in Canada. Global Fabry Disease Advisory Board Meeting, Boston MA, USA. Dec 5, 2008.
147. Ophthalmology Grand Rounds Fabry Disease: More than meets the eye. Department of Ophthalmology and Visual Sciences. Dalhousie University, Halifax NS. Feb. 11, 2009.
148. Fabry Nephropathy: the never-ending story. Visiting Lecturer. Shire Human Genetic Therapies Inc, Boston MA, USA. Feb. 12, 2009.
149. Fabry Disease: everything a dermatologist needs to know. Dermatology Rounds. QE II Health Sciences Centre, Halifax NS, March 13, 2009.
150. New Insights into the long-term treatment of Fabry nephropathy. Fabry Global Advisory Board, Frankfurt Germany, Apr. 22, 2009.
151. ACE inhibitors and ARBs in Fabry Disease: Rescue or Peril? 9th International Symposium on Lysosomal Storage Diseases, Frankfurt Germany, Apr. 25, 2009.

152. Treatment of Fabry Nephropathy: Synergy of agalsidase and RAS Inhibitors. LSD Club 2009 Montreal QC, June 4, 2009.
153. Fabry Disease in Canada: Clinical Practice and Access Guidelines. Canadian Fabry Association Annual Meeting, Halifax NS, Sept 19, 2009.
154. Neurosciences Rounds: What Every Neurologist Needs to Know About Fabry Disease, QE II Health Sciences Centre, Halifax NS, Sept 30, 2009.
155. Canadian Fabry Disease Initiative (CFDI) Study Update. Fabry Global Advisory Board Meeting. Barcelona, Spain. Nov. 4, 2009.
156. Experience of Management of Patients with Fabry Disease: Update from the Canadian Fabry Disease Initiative (CFDI) study. International Workshop on Lysosomal Storage Disorders, Barcelona, Spain. Nov. 8, 2009.
157. Management of the Patient with an Elevated Serum Creatinine. Dalhousie CME Videoconference. Halifax NS. Nov. 25, 2009.
158. What Every Neurologist Needs to Know About Fabry Disease. Neurology Rounds, Division of Neurology, Department of Medicine, University of Alberta. Edmonton AB. Nov. 27, 2009.
159. Fabry Disease: What Every Nephrologist Needs to Know. Nephrology Grand Rounds, Division of Nephrology, Department of Medicine, University of Alberta. Edmonton AB. Nov. 27, 2009.
160. Fabry Disease: an uncommon but treatable disease. Keynote Address. 4th Annual Fabry Disease Symposium, Tokyo Prince Hotel, Tokyo, Japan. Feb. 27, 2010.
161. Fabry Disease: an uncommon but treatable disease. Special Lecture, Fabry disease Symposium, Hotel Okura, Kobe, Japan. Mar. 1, 2010.
162. Canadian Fabry Disease Initiative (CFDI) Update. Fabry Expert Advisory Group, Park Plaza Hotel, London UK. Mar. 23, 2010.
163. Fabry Disease: an uncommon but treatable disease. Everything a cardiologist should know. Cardiology Grand Rounds, QE II Health Sciences Centre, Halifax NS. Mar. 29, 2010.
164. Fabry Disease: What every nurse should know. Bayshore Replagal Nurse Education Day, Halifax NS. April 9, 2010.
165. The CFDI study: What every nurse needs to know. Bayshore Replagal Nurse Education Day, Halifax NS. April 9, 2010.

166. Fabry Nephropathy: from deposits to dialysis. Advances in Lysosomal Storage Diseases, Park Hyatt Hotel, Toronto, ON. May 6, 2010.
167. FOS Pediatric Data Review. FOS Canada Review Meeting, Park Hyatt Hotel, Toronto, ON. May 7, 2010.
168. Anderson Fabry Disease and the Kidney. Cardiomyopathy Association Symposium on Anderson Fabry Disease and the Heart, London UK. May 22, 2010.
169. The CFDI Study at Year Three. LSD Club Meeting, Auberge Sainte-Antoine, Quebec City, QC. June 3, 2010.
170. Renal Manifestations of Fabry Disease. Fabry Masterclass Brazil, Salvador Brazil. Sept. 10, 2010.
171. The Canadian Fabry Disease Initiative Study at Year Three. Fabry Masterclass Brazil, Salvador, Bahia, Brazil. Sept. 10, 2010.
172. Fabry Nephropathy: What every nephrologist needs to know. Brazilian Congress of Nephrology, Vitorio, Espirito Santo, Brazil. Sept. 12, 2010.
173. Fabry Disease: New treatments for an old Maritime disease. Grand Rounds, Department of Medicine, Saint John Regional Hospital, Saint John, NB. Sept. 23, 2010.
174. Fabry Nephropathy: What everyone needs to know. Continuing Nursing Education, Nova Scotia Nephrology Nurses Group, QE II Health Sciences Centre, Halifax NS. Sept. 28, 2010.
175. Fabry Disease: New treatments for an old Nova Scotia disease. Medical Genetics Rounds, Department of Pediatrics, IWK Health Centre for Women and Children, Halifax NS. Sept. 28, 2010.
176. Current evidence for the long-term efficacy of ERT in Fabry Disease. International Workshop on Lysosomal Storage Diseases, Prague, Czech Republic. Dec. 4, 2010.
177. Fabry Disease Workshop: Principles of Treatment of Renal Disease. International Workshop on Lysosomal Storage Diseases, Prague, Czech Republic. Dec. 4, 2010.
178. Fabry Disease in Nova Scotia: something old and something new. Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax NS. Jan. 6, 2011.
179. Diagnosing Fabry disease: needle in the haystack or right under your nose?

- Department of Medicine, Cape Breton District Health Authority, Sydney NS. Jan. 25, 2011.
180. Fabry Disease: What everyone needs to know. Continuing Nursing Education, Nova Scotia, Teleconference, QE II Health Sciences Centre, Halifax NS. Jan. 26, 2011.
 181. 15th year of clinical experience with Replagal worldwide: What have those years shown us? 5th Replagal Anniversary Meeting in Argentina: Making history in Fabry Disease, Buenos Aires, Argentina August 5, 2011.
 182. Fabry Disease: Needle in a haystack or right under your nose? St. Johns NL. Sept.20, 2011.
 183. Fabry Disease: Needle in a haystack or right under your nose? Nephrology Rounds, Georges Dumont Hospital, Moncton NB. Oct. 5, 2011.
 184. Fabry Disease and the CFDI: a tangled tale. Genzyme Corporation. Cambridge, MA, USA. Jan. 10, 2012.
 185. Prospective Results of Switching Enzyme Replacement Therapy from Agalsidase beta to Agalsidase alfa in the Canadian Fabry Disease Initiative Study. Shire HGT Advisory Board, Orlando, FLA, USA. Jan. 11, 2012.
 186. Management of Chronic Kidney Disease, CME Videoconference, Dalhousie University, Halifax NS. Jan. 19, 2012.
 187. Fabry Disease in Nova Scotia. IGNITE GE3LS Presentation. International Rare Diseases Day event. Dalhousie University, Halifax NS. Feb. 29, 2012.
 188. Treatment strategies in Fabry disease? How can the latest experience be translated to clinical practice. 11th International Workshop on Lysosomal Storage Diseases, London UK. Mar. 2,3, 2012.
 189. Three years on: Summarizing the Fabry disease switch experience. 11th International Workshop on Lysosomal Storage Diseases, London UK. Mar. 2, 2012.
 190. A Tale of Two Diseases: Balkan endemic nephropathy and aristolochic acid nephropathy. Division of Nephrology, Department of Medicine, University of Western Ontario, London ON. March 26, 2012.
 191. Diagnosing Fabry Disease: needle in a haystack or right under your nose? Nephrology Rounds, Department of Medicine, University of Western Ontario, London, ON. March 26, 2012.
 192. Year Five of the CFDI: What have we learned? Genzyme Canada, Halifax NS.

March 28, 2012.

193. The Nova Scotia Fabry Kindred and the Kidney in Fabry Disease. 2012 Canadian Healthcare Advocates Meeting. Halifax NS. March 29, 2012.
194. Switching Fabry patients between agalsidase alfa and agalsidase beta. Shire Advisory Board Meeting. Halifax NS. June 8, 2012.
195. The future needs of ERT in Fabry disease. Shire Advisory Board Meeting. Halifax NS. June 8, 2012.
196. Fabry disease in Canada 2012. Jikei University, Tokyo Japan. July 20, 2012.
197. Use and comparison of ERT in Fabry disease: the CFDI study. National Taiwan University Hospital, Taipei Taiwan. July 23, 2012.
198. Prospective results of switching ERT from agalsidase beta to agalsidase alfa in the CFDI study. National Taiwan University Hospital, Taipei Taiwan. July 23, 2012.
199. The Canadian Fabry Disease Initiative study of enzyme replacement therapy: head to head trial comparing two enzymes. Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. July 24, 2012.
200. Case discussions in Fabry Nephropathy. Kaohsiung Veterans General Hospital, Kaohsiung Taiwan. July 25, 2012.
201. Round Table Discussion of Issues in Fabry Disease. Fabry Expert Workshop, Mexico City, Mexico. Sept. 28, 2012.
202. The Canadian Fabry Disease Initiative: What we can learn from the switch experience? Fabry Expert Workshop, Mexico City, Mexico. Sept. 29, 2012.
203. The CFDI Study 2012. Division of Endocrinology and Metabolism. Academic Medical Center, Amsterdam, The Netherlands. Oct. 23, 2012.
204. Case Studies in Fabry Disease. St. John's NL. Nov. 1. 2012.
205. Fabry Disease: New treatments for an old disease. Medical Grand Rounds, Department of Medicine, St. John's Health Sciences Centre, St. John's, NL. Nov. 2, 2012.
206. CFDI: Outcomes and Antibodies. Genzyme Corporation. Naarden, The Netherlands. Nov. 29, 2012.
207. Fabry Disease: New treatments for an old disease. Medical Grand Rounds,

- Department of Medicine, Health Sciences Centre, Winnipeg, MB. Dec. 11, 2012.
208. Fabry Disease: New treatments for an old disease. Nephrology Rounds, Department of Medicine, Queen's University, Kingston ON. March 22, 2013.
 209. Case Studies in Fabry Disease. Medical Genetics Rounds, Department of Pediatrics, Queen's University, Kingston ON. March 22, 2013.
 210. Fabry Disease: What every internist needs to know. Internal Medicine Education Day. Bridgewater NS. April 6, 2013.
 211. CFDI 2013. A Step in the Right Direction. LSD Club Meeting, Montreal QC. May 10, 2013.
 212. The CFDI Study and Switch of Enzyme Replacement Therapy. Hong Kong, China. June 4, 2013.
 213. Fabry Nephropathy Guidelines 2013. Third Update on Fabry Nephropathy. Biomarkers, Progression and Treatment Opportunities. Hong Kong, China. June 4,5, 2013
 214. Enzyme Replacement Therapy in Fabry Disease. Kidney and Lipids, World Congress of Nephrology Satellite Symposium, Fukuoka, Japan. June 7, 2013.
 215. The CFDI Study: Enzyme Replacement Therapy and Antibodies, Osaka, Japan. June 8, 2013.
 216. Fabry Disease and the CFDI study: Meet the Expert. Barcelona Spain. Sept. 4, 2013.
 217. Management of Chronic Kidney Disease: Tips and Pitfalls. General Internal Medicine Rounds, QE II Health Sciences Centre, Halifax NS. Nov. 14, 2013.
 218. Fabry Disease and the Kidney. Nordic and Baltic Fabry Meeting, Oslo, Norway. Nov. 20, 2013.
 219. Fabry Disease and the CFDI Study. Meet the Expert. Manchester Grand Hyatt Hotel. San Diego CA USA. Feb. 11, 12, 2014.
 220. Management of Chronic Kidney Disease: Tips and Pitfalls. Dalhousie University CME, South Shore Regional Hospital, Bridgewater NS. April 10, 2014.
 221. Workshop: The Challenges of Managing Kidney Manifestations of Fabry Disease. Fabry Masterclass IV Meeting, Prague, Czech Republic. May 16-17, 2014.
 222. Latest Update from the Canadian Fabry Disease Initiative (CFDI). London UK, May

- 12, 2014. LSD Study Day Birmingham Children's Hospital and University Hospital Birmingham, Birmingham UK, May 13, 2014. Manchester UK, May 13, 2014. Adult Metabolic Disease Unit, Mater Misericordia Hospital, Dublin IE, May 14, 2014. Fabry Masterclass IV Meeting, Prague Czech Republic, May 17, 2014.
223. Slowing Nephropathy Progression: Focus on Proteinuria Reduction. Ist LATAM Fabry Masterclass Meeting. Buenos Aires, Argentina. Aug. 28-29, 2014.
224. 5 Years Experience with the Canadian Fabry Disease Initiative (CFDI): what all those years can teach us. Ist LATAM Fabry Masterclass Meeting. Buenos Aires, Argentina. Aug. 28-29, 2014.
225. Canadian Fabry Disease Initiative: lessons learned. Fabulous Females of Fabry Disease. Oak Island Resort, Martins River NS. Sept 27-28, 2014.
226. A Potpourri of Female Fabry Disease. Fabulous Females of Fabry Disease. Oak Island Resort, Martins River NS. Sept 27-28, 2014.
227. The Canadian Fabry Disease Initiative: an update. European Symposium on Lysosomal Storage Disorders, London UK. Nov. 21-22, 2014.
228. Fabry Disease and the Unmet Promise of Enzyme Replacement Therapy. Genetics Seminar Series, Dalhousie University, Halifax NS. April 22, 2015.
229. Fabry Disease: What Every Nephrologist Needs to Know in 2015. Toronto, Ontario, April 28, 2015.
230. Fabry Disease. EMS Annual Symposium, Oak Island Resort, Western Shore, Nova Scotia. May 2, 2015.
231. Workshop best practice sharing: Learning from the Canadian Fabry Disease Initiative (CFDI) on how to achieve the best outcomes for patients in the long term. Fabry Masterclass Meeting, Warsaw, Poland. May 9, 2015.
232. Optimising outcomes for patients: Insight from the Canadian Fabry Disease Initiative (CFDI). Fabry Masterclass Meeting, Warsaw, Poland. May 9, 2015.
233. Debate: Enzyme Replacement Therapy in Fabry Disease: Dose does not matter. 4th Symposium on Fabry Nephropathy, a Satellite meeting of the European Renal Association/European Dialysis and Transplant Association. Manchester UK. June 1-2, 2015.
234. Optimizing Outcomes for Patients: Insight from the Canadian Fabry Disease Initiative (CFDI). The Lin Hotel, Taichung, Taiwan. June 11, 2015.

235. Optimizing Outcomes for Patients: Insight from the Canadian Fabry Disease Initiative (CFDI). Veteran General Hospital, Kaohsiung, Taiwan. June 12, 2015.
236. Optimizing Outcomes for Patients: Insight from the Canadian Fabry Disease Initiative (CFDI). Chinese Medical Association Annual Meeting, Taipei, Taiwan. June 13, 2015.
237. CFDI Update. KDIGO Controversies Conference on Diagnosis and Management of Patients with Fabry Nephropathy, Dublin IE. Oct. 15-17,2015.
238. Genotype-Phenotype Correlations in Fabry Disease. Workshop at European Symposium on Lysosomal Storage Diseases, Barcelona, SP. Oct. 23, 2015.
239. What is evidence-based medicine telling us about ERT in Fabry disease-8 year outcomes of the CFDI. Workshop at European Symposium on Lysosomal Storage Diseases, Barcelona, SP. Oct. 24, 2015.
240. Clinical Presentation of Fabry Disease at Genzyme sponsored Roundtable on Fabry Nephropathy. San Diego CA USA, Nov 5, 2015.
241. Fabry Disease: the Brave New World of Therapies for Genetic Disease. Medical Grand Rounds, Department of Medicine, Dalhousie University, Halifax NS. Nov. 17, 2015.
242. Fabry Disease: What every nephrologist should know in 2016. Qu'Appelle Renal Unit, Regina SK. Jan. 14, 2016.
243. Fabry Disease: What everyone should know in 2016. Medical Staff Meeting, Regina SK. Jan. 14, 2016.
244. Fabry Disease: What every nephrologist should know in 2016. Nephrology Rounds, Regina General Hospital, Regina SK. Jan. 15, 2016.
245. Fabry Disease: Update 2016. Internal Medicine Rounds, Sydney Nova Scotia. Feb. 16, 2016.
246. Update on the CFDI Study 2016. Annual Scientific Committee Meeting FACTS study, Langdon Hall, Cambridge ON Mar. 12, 2016.
247. Alemtuzumab-Associated Kidney Disease, Sydney NS. April 6, 2016.
248. What has evidence-based medicine taught us about enzyme replacement therapy in patients with Fabry disease? Fabry Masterclass VIII Meeting, Riga, Latvia. April 22-23, 2016.

249. Fabry Guidelines Presentation. Fabry Masterclass VIII Meeting, Riga, Latvia. April 22-23, 2016.
250. Fabry Disease: from genes to protein and back. Gene therapy. Canadian Fabry Association Annual Meeting, Halifax NS. May 8, 2016.
251. CFDI Update 2016. Canadian Fabry Disease Initiative Annual Scientific Meeting, Halifax NS. May 18, 2016.
252. Management and Outcomes in Adults with Fabry Disease-Lessons from the CFDI Study. Fabry Disease Symposium. Garrod Symposium 2016, Halifax NS. May 19, 2016.
253. Outcomes in Fabry Nephropathy. Asian Fabry Disease Masterclass Meeting. Seoul, South Korea. Sept.24-25, 2016.
254. Fabry Disease Screening in the Renal Clinic. Asian Fabry Disease Masterclass Meeting. Seoul, South Korea. Sept.24-25, 2016.
255. Outcomes of the Canadian Fabry Disease Initiative. Asian Fabry Disease Masterclass Meeting. Seoul, South Korea. Sept.24-25, 2016.
256. Polycystic Kidney Disease. Dalhousie CME. Queen's Memorial Hospital, Liverpool NS. Oct. 20, 2016.
257. Fabry Disease. Video presentation. Ukidney.com Nov. 11, 2016.
258. Fabry Disease: What every neurologist should know in 2016. Division of Neurology, Georges Dumont Hospital, Moncton NB. Nov 17, 2016.
259. Outcomes from the Canadian Fabry Disease Initiative Study, Division of Cardiology and Geriatrics, Kochi University Medical School, Kochi Japan. March 2, 2017.
260. Outcomes from the Canadian Fabry Disease Initiative Study, Division of Nephrology, Nagoya University Medical School, Nagoya Japan. March 3, 2017.
261. Outcomes from the Canadian Fabry Disease Initiative Study, Fabry Disease Ten Year Symposium, Tokyo Ariake Conference Centre, Tokyo Japan. March 4, 2017.
262. Outcomes from the Canadian Fabry Disease Initiative Study and Antidrug Neutralizing Antibodies. 5th Annual Langdon Hall Meeting on Gene Transfer Therapy in Fabry Disease, Cambridge ON, Canada. April 7, 2017

PRESENTATIONS AT CONFERENCES (NON-INVITED)

1. **WEST ML**, Chen CB, Singer GG, Richardson RMA, Sonnenberg H, Halperin ML. A Non-invasive Method to Evaluate the Renal Response to Aldosterone (ALDO) In Vivo. Clinical Research Society of Toronto Annual Meeting, Toronto. April 1985.
2. **WEST ML**, MacSween JM, Rajaraman K, Cohen AD. Lymphokine Responses in Renal Transplant Recipients with and without Cancer. Royal College of Physicians and Surgeons of Canada Annual Meeting, Vancouver. September 1985.
3. **WEST ML**, Marsden P, Singer GG, Halperin ML. Glucose Balance During Recovery from Hyperglycemic Hyperosmolar Syndrome (HHS). Royal College of Physicians and Surgeons of Canada Annual Meeting, Vancouver. September 1985.
4. **WEST ML**, Chen CB, Singer GG, Richardson RMA, Halperin ML. An Improved Clinical Method to Evaluate the Renal Response to Aldosterone In Vivo. Canadian Society for Clinical Investigation Annual Meeting, Vancouver. September 1985
5. **WEST ML**, Zettle RM, Sonnenberg H, Halperin ML. Mechanisms Responsible for Potassium (K) Excretion in Adrenalectomized (Adx) Rats. Clinical Research Society of Toronto Annual Meeting, Toronto. April 1986.
6. Jindal K, **WEST ML**, Bear R, Goldstein M. Benefit of Cyclophosphamide Therapy (CT) in Patients with Membranous Glomerulonephritis (MGN) and Impaired Renal Function. Royal College of Physicians and Surgeons of Canada Annual Meeting, Toronto. September 1986.
7. **WEST ML**, Margolis B, Robinson L, Halperin R, Halperin ML. The Urine Osmolar Gap: A Clinical Clue for Occult Ketoacidosis. Royal College of Physicians and Surgeons of Canada Annual Meeting, Winnipeg, September 13, 1987.
8. **WEST ML**, Halperin ML. Potassium Excretion in Severely Hyperglycemic Patients: A Reversible Diminished Response to Aldosterone. Royal College of Physicians and Surgeons of Canada Annual Meeting, Winnipeg, September 13, 1987.
9. **WEST ML**, Dyck RF, Cunningham TA. Immunosuppressive Treatment of Severe IgA Nephropathy. Royal College of Physicians and Surgeons of Canada Annual Meeting Toronto, September 15, 1990.
10. Nicol D, MacDonald AS, Belitsky P, Bitter-Suermann H, Lawen J, Cohen A, Hirsch D, **WEST M**, Jindal K. Combination Prophylactic Therapy with CMV Hyperimmune Globulin and Acyclovir Reduces the Risk of primary CMV Disease in Renal Transplant Recipients. XIVth International Congress of the Transplantation Society, Paris, August 16-21, 1992.
11. **WEST ML**, Jindal KK. Peritonitis Presenting as Acute Catheter Obstruction in Non Continuous Forms of Peritoneal Dialysis (PD). Department of Medicine Research Day,

- Victoria General Hospital, Halifax, N.S., May 7-8, 1992. VIth Congress of the International Society for Peritoneal Dialysis, Thessaloniki, Greece, October 1-4, 1992.
12. Jindal K, Hirsch, **WEST M**, Cohen A. Chronic Ambulatory Peritoneal Dialysis (CAPD). Excellent Technique and Patient Survival without Formal Dialysis Adequacy Assessment. VIth Congress of the International Society for Peritoneal Dialysis, Thessaloniki, Greece, October 1-4, 1992.
 13. **WEST ML**, Prabhu U, Gupta R. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Glomerulonephritis in Nova Scotia (NS) 1990-91. The Royal College of Physicians and Surgeons of Canada Annual Meeting, Vancouver, September 10-13, 1993.
 14. **WEST ML**, Trillo A. Kappa Light Chain Deposition Disease (K-LCDD) Complicated by Hypopituitarism. The Royal College of Physicians and Surgeons of Canada Annual Meeting, Vancouver, September 10-13, 1993. Clin Invest Med 1993.
 15. Logan H, Sketris I, **WEST M**. Effect of Angiotensin Converting Enzyme Inhibitors on Kidney Function in Renal Transplant Patient Receiving Cyclosporine. The Canadian Society of Hospital Pharmacists 24th Annual Professional Practice Conference, Toronto, January 31-February 4, 1993.
 16. Salazar AB, Lawen JG, Al-Khudair W, Gupta R, Bitter-Suermann H, MacDonald AS, McAlister V, **WEST M**, Belitsky P. Fate of Second Kidney Transplants When the First was Lost from Rejection in the First Week. The Royal College of Physicians and Surgeons of Canada Annual Meeting, Vancouver, September 10-13, 1993.
 17. Sketris I, Waite N, Grobler K, **WEST M**. Cyclosporine Use in Renal Transplant Patients. Canadian Society of Hospital Pharmacists 25th Annual Professional Practice Conference, Toronto, February, 1994.
 18. Sketris IS, Waite N, Grobler K, **WEST M**. Factors Affecting Patient Compliance with Cyclosporine in Renal Transplant Patients. The Third International Congress on Cyclosporine Meeting, Seville, Spain, March 29-31, 1994.
 19. Dhar J, Macneil A, Boss S, Fraser A, **WEST M**. Spurious Evaluation of Serum Creatinine Caused by Ingestion of Model Airplane Fuel. The Dalhousie University Department of Medicine Research Day, Halifax, NS, May 5, 1994.
 20. Sepandj F, Jindal K, **WEST M**, Hirsch D. Economic Appraisal of Maintenance Parenteral Iron Administration in Treatment of Anemia in Chronic Hemodialysis Patients. American Society of Nephrology Annual Meeting, Orlando, FL, October 26-29, 1994.
 21. **WEST M**, Fraser A, Boss S, Dhar J, Macneil A, Schuberth J. False Elevation of the Serum Creatinine (sCR) by Ingestion of Model Airplane Fuel. The Department of Medicine Research Day, Dalhousie University, May 4,5, 1995. The Royal College of

- Physicians and Surgeons of Canada Annual Meeting, Montreal, QC, September 15-18, 1995.
22. Sobkowski V, **WEST M.** Acute Renal Failure Related to Concurrent Administration of Low Dose Methotrexate (MTX) and Diclofenac. Department of Medicine Research Day, Dalhousie University, May 4,5, 1995.
 23. White DJ, Nevill TJ, Hayne OA, **WEST ML.** Steroid-Resistant Nephrotic Syndrome Secondary to Chronic Graft-Versus-Host Disease (GVHD) Responding to Pulse Cyclophosphamide (CY). Royal College of Physicians and Surgeons of Canada Annual Meeting, Halifax, NS, September 26-29, 1996.
 24. Keough-Ryan TM, **WEST ML.** Renal Failure Secondary to Procidencia. Department of Medicine Research Day, Dalhousie University, Halifax, NS, May 1, 1997 and The Royal College of Physicians and Surgeons of Canada Annual Meeting, Vancouver, BC, September 25-28, 1997.
 25. Koren S, **WEST M:** Sarcoidosis With Resistant Hypercalcemia - A Diagnostic Challenge. The Department of Medicine Research Day, Dalhousie University, Halifax, N.S., May 7, 1998.
 26. Panek R, **WEST ML,** Geldenhuys L. Fibronectin Glomerulonephritis Presenting with Rapid Decline in Renal Function and Hypersensitivity Features. Can Soc Nephrol Meeting Vancouver BC March 2001 and Am Soc Nephrol Meeting San Francisco CA October 10-17, 2001.
 27. Thadhani R, Wolf M, Tonelli M, **WEST ML,** Obrador G. Fabry Disease Patients on Dialysis in the US and Europe: A Comparison Study. Am Soc Nephrol Meeting San Francisco CA October 10-17, 2001.
 28. Thadhani R, Wolf M, **WEST ML,** Tonelli M, Obrador G. Patients with Fabry Disease on Dialysis in the United States. Am Soc Nephrol Meeting San Francisco CA October 10-17, 2001.
 29. **WEST ML,** Dyack S, Riddell C, Lemoine K, Camfield C, Camfield P. A Nova Scotia Kindred with Fabry Disease. 2nd International Symposium on Lysosomal Storage Diseases, Cannes, France, April 26-27, 2002 and American Society Human Genetics Baltimore October 15-19 2002.
 30. **WEST ML,** Lemoine K, Simms C, Dyack S. Cross-Sectional Analysis of Renal Disease in the Nova Scotia Fabry Disease Kindred. 2nd International Symposium on Lysosomal Storage Diseases, Cannes, France, April 26-27, 2002 and American Society of Nephrology Annual Meeting Philadelphia October 30-November 4 2002.
 31. **WEST ML,** Lemoine K, McKillip R, Harnett J. Renal Transplantation in the Nova

- Scotia Fabry Disease Kindred. 2nd International Symposium on Lysosomal Storage Diseases, Cannes, France, April 26-27, 2002 and American Society of Nephrology Annual Meeting Philadelphia October 30-November 4 2002.
32. Thanamayooran S., **WEST M.**, Dyack S. LeMoine K., Riddell C and Simms C. A Fabry Disease Homozygote in the Nova Scotia Kindred with Classic Hemizygote Phenotype. Resident Research Day, Department of Medicine, Dalhousie University, Halifax, NS April 17, 2003. 3rd International Symposium Lysosomal Storage Disease, Santiago de Compostela, Spain May 17, 2003.
 33. **WEST M.**, for the Canadian Expert Working Group on Fabry Disease. Fabry Disease: Recommendations for Diagnosis, Management and Enzyme Replacement Therapy with Human Recombinant α -Galactosidase in Canada. 4th International Symposium Lysosomal Storage Disease, Seville, Spain April 23-24, 2004. Canadian Society of Nephrology Annual Meeting. Toronto, ON. May 31, 2004. American Society of Human Genetics Annual Meeting Toronto ON. Oct. 28, 2004.
 34. Poepl AG, LeMoine K, Hewlett T, Dhar J, **WEST M.**, Medin JA. Enhanced Filter Paper Enzyme Assay for High-Throughput Population Screening for Fabry Disease. World Organization for Research on Lysosomal Storage Diseases Annual Symposium. Minneapolis Minn. May 13-15, 2004.
 35. **WEST M.**, Geldenhuys L, LeMoine K. Progressive Fabry Disease Nephropathy in a Female Heterozygote. Canadian Society of Nephrology Annual Meeting. Toronto, ON. May 31, 2004.
 36. **WEST M.**, Medin J, LeMoine K, Poepl A, Hewlett T, Dhar J. A Screening Study for Fabry Disease in Renal Transplant and Dialysis Patients in Nova Scotia. American Society of Human Genetics Annual Meeting Toronto, ON. Oct. 28, 2004.
 37. LeMoine K, **WEST M.**, Simms C, MacLennan F. Home Enzyme Replacement Therapy with Replagal for Fabry Disease in Nova Scotia. American Society of Human Genetics Annual Meeting Toronto, ON. Oct. 28, 2004.
 38. Waldek S. on behalf of the Phase 4 Trial Collaborators (**incl. M. WEST**). Clinical Benefit of Fabrazyme Agalsidase Beta Therapy in Fabry Disease: Results of the Phase 4 Study. Second Symposium on Lysosomal Storage Disorders. Athens, Greece. March 2-4, 2005.
 39. **WEST M.**, LeMoine K. Effect of Changing Therapy from Agalsidase- β to Agalsidase- α in Fabry Disease. 5th International Symposium on Lysosomal Storage Diseases, Valencia, Spain. April 15-16, 2005, 9th Annual LSD Registries Meeting, Phoenix AZ USA, May 21, 2005, FIRE Investigator Meeting, Boston, MA, USA, June 24, 2005 and Canadian Society of Nephrology Annual Meeting, Quebec City QC May 27, 2006.

40. **WEST M**, Geldenhuys, L, LeMoine K. Response of Rapidly Progressive Fabry Disease Nephropathy in a Female to Enzyme Replacement Therapy. 5th International Symposium on Lysosomal Storage Diseases, Valencia, Spain. April 15-16, 2005, 9th Annual LSD Registries Meeting, Phoenix AZ USA, May 21, 2005.
41. **WEST M**, LeMoine K. A five year experience with enzyme replacement therapy in Fabry Disease in Nova Scotia. FIRE Investigator Meeting, Boston, MA, USA, June 24, 2005.
42. **WEST M**, LeMoine K. Mainz severity score index and enzyme replacement therapy in Fabry disease in Nova Scotia. 6th European Round Table on Fabry Disease, Geneva Switzerland, Oct. 21-22, 2005, Department of Medicine Faculty Research Day, Halifax NS Nov. 3, 2005 and Canadian Society of Nephrology Annual Meeting, Quebec City QC May 27, 2006.
43. Waldek S. on behalf of the AGAL-008-00 Investigators of the International Fabry Disease Study Group (**incl. M. WEST**). Proteinuria Signals the Risk of Disease Progression as Strongly in Female as in Male Patients with Fabry Disease. 6th European Round Table on Fabry Disease, Geneva Switzerland, Oct. 21-22, 2005.
44. **WEST M**, LeMoine K. Effect of Withdrawal of Enzyme Replacement Therapy in Fabry Disease. 6th International Symposium on Lysosomal Storage Disease, Stockholm, Sweden April 28-29, 2006.
45. Clarke J, **WEST M**, Schiffmann R, Bultas J, Askari M, Brady RO. Alternative Dosing Regimens of Agalsidase alfa (Replagal) in Fabry Disease. American Society of Human Genetics Annual Meeting, New Orleans, USA, Oct. 10, 2006.
46. **WEST M**, LeMoine K. Withdrawal of Enzyme Replacement Therapy in Fabry Disease: Indirect Evidence of Benefit? 7th European Round Table on Fabry Disease, Barcelona Spain Oct. 27-28, 2006.
47. Waldek S. on behalf of the AGAL-008-00 investigators of the International Fabry Disease Study Group (**incl. M. WEST**). Proteinuria Signals the Risk of Disease Progression as Strongly in Female as in Male Patients with Fabry Disease. 7th European Round Table on Fabry Disease, Barcelona Spain Oct. 27-28, 2006.
48. Fogo A, Oliveira J-P, Waldek S, Warnock D. on behalf of the International Fabry Kidney Biopsy Working Group (IFBWG) (**incl. M. WEST**) Developing a Chronicity Index for Kidney Involvement in Fabry Disease. American Society of Nephrology Annual Meeting, San Diego CA, USA. Nov. 16-19, 2006.
49. Cybulla M, Schwarting A, Barbey F, Feriozzi S, Sunder-Plasmann G, **WEST M**. Proteinuria in Fabry Nephropathy during Enzyme Replacement Therapy (ERT). American Society of Nephrology Annual Meeting, San Diego CA, USA. Nov. 16-19,

2006. Canadian Society of Nephrology Annual Meeting, Halifax NS, May 26, 2007.
50. **WEST M**, Nicholls K, Clarke J, Steiner R, Mehta A, Schiffmann R. Effects of Long-term Agalsidase-alfa (Replagal)[®] Therapy on Renal Function in Male Fabry Patients. American Society of Nephrology Annual Meeting, San Diego CA, USA. Nov. 16-19, 2006.
 51. **WEST M**, LeMoine K. Withdrawal of Enzyme Replacement Therapy in Fabry Disease: Indirect Evidence of Benefit? 3rd Annual WORLD Symposium, Orlando, FLA, USA. Dec. 7-9, 2006.
 52. Clarke J, **WEST M**, Schiffmann R, Bultas J, Askari M, and Brady RO. Alternative Dosing Regimens of Agalsidase alfa (Replagal) in Fabry Disease. 3rd Annual WORLD Symposium, Orlando, FLA, USA. Dec. 7-9, 2006.
 53. **WEST M**, Bichet D, Casey R, Clarke J, Clarke L, and Sirrs S. Canadian Fabry Disease Initiative (CFDI): A Prospective Randomized Trial Of Enzyme Replacement Therapy (ERT) In Fabry Disease. 7th International Symposium on Lysosomal Storage Diseases, Rome, Italy, April 27,28 2007, Canadian Society of Nephrology Annual Meeting, Halifax NS, May 26, 2007.
 54. **WEST M**, Cybulla M, Feriozzi S, Schwarting A, Sunder-Plassmann G, Schiffmann R, Mehta A on behalf of the FOS Investigators. Effect of Agalsidase alfa on the decline in renal function in patients with Fabry disease. Canadian Society of Nephrology Annual Meeting, Halifax NS, May 26, 2007. European Dialysis and Transplant Association Annual Meeting, Barcelona, Spain. June 21-24, 2007.
 55. Tennankore K, **WEST M**, LeMoine L. Effect of withdrawal of enzyme replacement therapy in Fabry disease. Canadian Society of Nephrology Annual Meeting, Halifax NS, May 26, 2007.
 56. Al-Ameel T, **WEST M**. Tranexamic acid treatment of life threatening hematuria in polycystic kidney disease. Canadian Society of Nephrology Annual Meeting, Halifax NS, May 26, 2007.
 57. Tennankore K, LeMoine K, **WEST M**. Withdrawal of Enzyme Replacement Therapy in Fabry Disease - Indirect Evidence of Treatment Benefit? American Society of Nephrology Annual Meeting, San Francisco CA, USA. Nov. 1-5, 2007 and Department of Medicine, Resident Research Day, Dalhousie University, Halifax NS April 17, 2008.
 58. Sunder-Plassmann G, Deegan P, Nicholls K, Feriozzi S, Schwarting A, Cybulla M, **WEST M**, Mehta A, FOS Investigators. Predictive performance of GFR estimates in 158 patients with Fabry disease. American Society of Nephrology Annual Meeting, San Francisco CA, USA. Nov. 1-5, 2007.

59. **WEST M**, Cybulla M, Feriozzi S, Schwarting A, Sunder-Plassmann G. Effect of Agalsidase Alfa on the Decline in Renal Function in Fabry Nephropathy. American Society of Nephrology Annual Meeting, San Francisco CA, USA. Nov. 1-5, 2007.
60. Auray-Blais C, Cyr D, Ntwari A, **WEST ML**, Cox-Brinkman J, Bichet DG, Germain DP, Laframboise R, Melançon SB, Stockley T, Clarke JTR, Drouin R. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. American Society of Human Genetics Annual Meeting, San Diego USA, Oct. 25, 2007.
61. Sirrs SM, Casey R, Clarke JTR, Bichet DG, LeMoine K, and **WEST ML**. Baseline characteristics of patients in the Canadian Fabry Disease Initiative. The Society of Inborn Errors of Metabolism Annual Meeting. Lisbon Portugal Sept 2-5, 2008.
62. **WEST M**, Bichet D, Casey R, Clarke J, Sirrs S. The Canadian Fabry Disease Initiative: a new paradigm for drug evaluation in Canada. Garrod Association Annual Meeting, Toronto ON. May 2-3, 2008, International Roundtable Meeting on Fabry Disease. Athens, Greece. Oct. 9-11, 2008.
63. Giannini EH, for the Anderson Fabry Disease DS3 Working Group including **WEST ML**. Progress in development and testing of reliability and validity of a disease severity scoring system for Anderson-Fabry disease. Annual Meeting American College of Medical Genetics. Tampa, FLA, USA. Mar. 25-29, 2009.
64. **WEST ML**, Nicholls K, Clarke JTR, Steiner RD, Mehta A, Schiffmann R. Clinical trial summary of agalsidase alfa and kidney dysfunction in Fabry Disease. Annual Meeting American College of Medical Genetics. Tampa, FLA, USA. Mar. 25-29, 2009.
65. **WEST M**, Flowerdew G, Bichet D, Casey R, Clarke J, Sirrs S, Auray-Blais C. The Canadian Fabry Disease Initiative: a randomized controlled trial of agalsidase therapy. International Roundtable Meeting on Fabry Disease. Athens, Greece. Oct. 9-11, 2008, Dalhousie University, Department of Medicine Research Day, Halifax NS, April 9, 2009.
66. **WEST M**, Flowerdew G, LeMoine K, Bichet D, Casey R, Clarke J, Sirrs S, Auray-Blais C. The Canadian Fabry Disease Initiative: a randomized controlled trial of agalsidase therapy. 9th International Symposium on Lysosomal Storage Diseases, Frankfurt Germany, April 25, 2009. Garrod Association Annual Meeting, Montreal QC, May 2, 2009. World Congress of Nephrology Satellite meeting. Fabry Nephropathy. Bergamo Italy. May 27, 2009.
67. Feriozzi S, **WEST M**, Cybulla M, Nicholls K, Mehta A, Schiffmann R, Beck M, Sunder-Plassmann. Effect of five years of agalsidase alfa on renal function in patients with Fabry disease. World Congress of Nephrology. Milan Italy, May 23, 2009.

68. Sirrs S, Clarke J, Bichet D, Casey R, LeMoine K, Flowerdew G, Auray-Blais C, **WEST M**. Canadian Fabry Disease Initiative - a RCT of ERT for Fabry disease. SSIEM Annual Meeting, San Diego CA, USA, Sept 4-7, 2009.
69. **WEST M**, Bichet D, Casey R, Clarke J, Sirrs S and Flowerdew G. Canadian Fabry Disease Initiative - a RCT of ERT for Fabry disease. 10th European Round Table on Fabry Disease, Prague, Czech Republic. Oct. 16-17, 2009.
70. Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, Geldenhuys L, **WEST M**, Ferluga D, Vujkovic B, Howie AJ, Burns A, Reeve R, Waldek S, Noel L-H, Grunfeld J-P, Valbuena C, Oliveira J-P, Muller J, Breunig F, Zhang X, Warnock D. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). 10th European Round Table on Fabry Disease, Prague, Czech Republic. Oct. 16-17, 2009.
71. Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, **WEST M**, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A. A validated disease severity scoring system for Fabry disease. 10th European Round Table on Fabry Disease, Prague, Czech Republic. Oct. 16-17, 2009.
72. **WEST M**, LeMoine K, Bichet D, Clarke J, Casey R, Sirrs S, Auray-Blais C. A randomized controlled trial of enzyme replacement therapy in Fabry nephropathy: the Canadian Fabry Disease Initiative at year two. American Society of Nephrology Annual Meeting, San Diego CA, USA. Oct. 29-Nov. 1, 2009.
73. Feriozzi S, **WEST M**, Cybulla M, Nicholls K, Torras J, Sunder-Plassmann G. Effects of more than 5 years of enzyme replacement therapy with agalsidase alfa on renal function in patients with Fabry disease. American Society of Nephrology Annual Meeting, San Diego CA, USA. Oct. 29-Nov. 1, 2009.
74. **WEST M**, LeMoine K, Bichet D, Clarke J, Casey R, Sirrs S, Auray-Blais C, Sinasac D, Flowerdew G. A Randomized Controlled Trial of Enzyme Replacement Therapy in Fabry Disease: The Canadian Fabry Disease Initiative at Year Three. 6th Annual WORLD Symposium 2010, Miami FLA, USA. Feb. 11, 2010.
75. **WEST M**, LeMoine K, Bichet D, Clarke J, Casey R, Sirrs S, Auray-Blais C, Sinasac D, Flowerdew G. A Randomized Controlled Trial of Enzyme Replacement Therapy in Fabry Disease: The Canadian Fabry Disease Initiative at Year Three. Garrod Association Annual Meeting, St. John's NL. June 25, 2010.
76. Sirrs S, Clarke J, Bichet D, Casey R, LeMoine K, Flowerdew G, **WEST M**. Agalsidase alfa and agalsidase beta have similar effects on Fabry outcomes - results from the Canadian Fabry Disease Initiative. SSIEM Annual Meeting, Istanbul Turkey. Aug 31, 2010.

77. **WEST M**, Bichet D, Casey R, Clarke J, Sirrs S, LeMoine K, Auray-Blais C. Influence of Anti-agalsidase Antibodies on Clinical Outcomes in the Canadian Fabry Disease Initiative Study. 11th European Round Table Meeting on Fabry Disease, Istanbul, Turkey. Oct. 15-16, 2010.
78. **WEST M**, Bichet D, Casey R, Clarke J, LeMoine K, Sirrs S. Agalsidase alfa and agalsidase beta have similar effects on Fabry outcomes – results from the Canadian Fabry Disease Initiative. 11th European Round Table Meeting on Fabry Disease, Istanbul, Turkey. Oct. 15-16, 2010.
79. **WEST M**, Bichet D, Casey R, Clarke J, Sirrs S, LeMoine K, Auray-Blais C. Influence of Anti-agalsidase Antibodies on Clinical Outcomes in the Canadian Fabry Disease Initiative Study. American Society of Nephrology Annual Meeting, Denver CO, USA. Nov.17-21, 2010.
80. Schiffmann R, Nicholl K, Mehta A, Clarke JTR, Steiner RD, Beck M, Barshop BA, Rhead WJ, **WEST M**, Martin R, Huertas P. Assessment of the utility of globotriaosylceramide as a surrogate marker based on randomized controlled trials in Fabry disease. American Society of Human Genetics Annual Meeting, Washington DC, USA. Nov 2-6, 2010.
81. **WEST ML**, Bichet DG, Casey R, Clarke JTR, Sirrs S, Flowerdew G and LeMoine K on behalf of the CFDI Investigators Group. The Canadian Fabry Disease Initiative at year four: Outcomes on enzyme replacement therapy. WORLD meeting, Las Vega, NV, USA. Feb. 16-18, 2011 and International Symposium on Lysosomal Storage Disorders, Madrid Spain. April 1-2, 2011.
82. **WEST M**, Schiffmann R, Mehta A, Amato D, Nair N, Zahrieh D, Huertas P. Enzyme replacement therapy with agalsidase alfa (Replagal) stabilizes renal function in male patients with Fabry disease: results of an integrated analysis. Society Inborn Metabolic Diseases 34th Annual Meeting, Asilomar, CA, USA. Feb. 27-Mar. 2, 2011, International Symposium on Lysosomal Storage Disorders, Madrid Spain. April 1-2, 2011, European Society of Human Genetics Amsterdam, Netherlands, May 28-31, 2011 and European Renal Association-European Dialysis and Transplant Association Meeting Prague, Czech Republic, June 25-26, 2011.
83. **WEST M**, Cornish M, Auray-Blais C, Hyndman S, Finkle N. Urine Gb3 can be elevated in the absence of Fabry Disease: implications for disease screening. Fabry Nephropathy: Biomarkers, Progression and Treatment Opportunities, Satellite Meeting of the World Congress of Nephrology, Vancouver BC. April 12-14, 2011, Research Day, Department of Medicine, Dalhousie University, Halifax NS. April 25, 2011 and Resident Research Day, Faculty of Medicine, Dalhousie University, Halifax NS. May 26, 2011.
84. **WEST ML**, Bichet DG, Casey R, Clarke JTR, Sirrs S, Flowerdew G and LeMoine K on behalf of the CFDI Investigators Group. The Canadian Fabry Disease Initiative at year

- four: Outcomes on enzyme replacement therapy. Fabry Nephropathy: Biomarkers, Progression and Treatment Opportunities, Satellite Meeting of the World Congress of Nephrology, Vancouver BC. April 12-14, 2011.
85. Feriozzi S, Torras, J, Cybulla M, Nicholls K, Sunder-Plassmann G, **WEST M**. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. European Renal Association-European Dialysis and Transplant Association Meeting Prague, Czech Republic. June 25-26, 2011.
86. Feriozzi S, Torras, J, Cybulla M, Nicholls K, Sunder-Plassmann G, **WEST M**. Cardiovascular risk in Fabry nephropathy. European Renal Association-European Dialysis and Transplant Association Meeting Prague, Czech Republic. June 25-26, 2011.
87. Sirrs S, Flowerdew G, Whyte J, Lemoine K, Bichet DG, Casey R, Clarke JTR, and **WEST ML** on behalf of the CFDI Investigators. Rate of decline of GFR in patients with Fabry disease (FD): Prospective natural history data from the Canadian Fabry Disease Initiative (CFDI). SSIEM Annual Meeting. Geneva, SW. Aug. 30-Sept. 2, 2011.
88. Schiffmann R, Blankenship D, Nicholls K, Mehta A, Clarke JTR, Steiner R, Beck M, Barshop B, Rhead W, **WEST M**, Martin R, Amato D, Nair N, Huertas P. Are globotriaosylceramide concentrations useful as surrogate markers to evaluate therapy for Fabry disease? SSIEM Annual Meeting. Geneva, SW. Aug. 30-Sept. 2, 2011.
89. **WEST M**, Bichet D, Casey R, Clarke J, Sirrs S, Flowerdew G, LeMoine K for the CFDI Investigators. Prospective Results of Switching Enzyme Replacement Therapy from Agalsidase beta to Agalsidase alfa in the Canadian Fabry Disease Initiative Study. 8th Annual WORLD Symposium, San Diego CA USA. Feb. 8-10, 2012. Canadian Society Nephrology meeting, St. John's NL. Apr 27-29, 2012. Garrod Association Meeting Winnipeg MB. May 3, 2012. Department of Medicine Research Day, Dalhousie University, Halifax NS. May 17, 2012.
90. Brinks V, Richards S, Ruiz J, Aerts H, von Landenberg P, **WEST M**, Breunig F, Wanner C, Wadhwa M. Fabry Disease Antibody Standardization Initiative (FASI). 8th Annual WORLD Symposium, San Diego CA USA. Feb. 8-10, 2012.
91. **WEST M**, Bichet D, Casey R, Clarke J, Sirrs S, Flowerdew G, LeMoine K for the CFDI Investigators. Five Year Comparison of Enzyme Replacement Therapy in the Canadian Fabry Disease Initiative Study. Canadian Society Nephrology Meeting, St. John's NL. Apr 27-29, 2012. Garrod Association Meeting Winnipeg MB. May 3, 2012. Department of Medicine Research Day, Dalhousie University, Halifax NS. May 17, 2012.
92. **WEST M**, Cornish M, Auray-Blais C, Hyndman S, Finkle N. Urine Gb3 can be elevated in the absence of Fabry Disease: implications for disease screening. Canadian Society Nephrology meeting, St. Johns NL. Apr 27-29, 2012.

93. Botros N, Alfaadhel T, **WEST M**, Geldenhuys L. Cast nephropathy with an apparently normal serum electrophoresis as a presentation of IgD myeloma- a rare entity. Canadian Association of Pathologists Annual Meeting, Calgary AB. May 3, 2012. Department of Medicine Research Day, Dalhousie University, Halifax NS. May 17, 2012.
94. Cybulla M, **WEST M**, Nicholls K, Torras J, Sunder-Plassmann G, Feriozzi S. Effectiveness and Safety of Enzyme Replacement Therapy (ERT) in a Cohort of Kidney Transplant Recipients with Fabry Disease. American Society of Nephrology, Annual Meeting, San Diego CA, USA. Oct. 30-Nov. 4, 2012.
95. Mauer M, Whitley CB, Svarstad E, Tøndel C, Gubler M-C, **WEST ML**, Najafian B. Structural-Functional Relationships of Fabry Nephropathy. American Society of Nephrology, Annual Meeting, San Diego CA, USA. Oct. 30-Nov. 4, 2012.
96. Najafian B, Whitley C, Thurberg BL, Svarstad E, Tøndel C, Gubler MC, **WEST ML**, Mauer M. Renal Structural-Functional Relationship Studies Suggest that Podocyte GL-3 Accumulation Predicts Urine Protein Creatinine Ratio in Patients with Fabry Disease (FD). 9th Annual WORLD Symposium, Orlando FLA, USA. Feb. 13-15, 2013.
97. Auray-Blais C, Boutin M, Lavoie P, Casey R, Clarke JTR, Foley SR, Keating A, Khan A, **WEST M**, Medin J. Gene Therapy for Fabry Disease Patients: The Importance of Efficient Biomarker Monitoring. 9th Annual WORLD Symposium, Orlando FLA, USA. Feb. 13-15, 2013.
98. **WEST M**, Bichet D, Casey R, Clarke J, Sirrs S, LeMoine K, Doucette S for the CFDI Investigators. Benefit of Enzyme Replacement Therapy in Fabry Disease: Comparison of Outcomes in the Canadian Fabry Disease Initiative Study. 9th Annual WORLD Symposium, Orlando FLA, USA. Feb. 13-15, 2013. Dalhousie University Department of Medicine Research Day, Halifax NS. April 11, 2013. Third Update on Fabry Nephropathy. Biomarkers, Progression and Treatment Opportunities, Hong Kong, China. June 4,5, 2013.
99. **WEST M**, Bichet D, Casey R, Clarke J, Sirrs S, Auray-Blais C, Aerts J, LeMoine K, Doucette S for the CFDI Investigators. Clinical Effects of Neutralizing Anti-agalsidase Antibodies in Patients Receiving Enzyme Replacement Therapy in the Canadian Fabry Disease Initiative Study. 9th Annual WORLD Symposium, Orlando FLA, USA. Feb. 13-15, 2013. Dalhousie University Department of Medicine Research Day, Halifax NS. April 11, 2013. Third Update on Fabry Nephropathy. Biomarkers, Progression and Treatment Opportunities, Hong Kong, China. June 4,5, 2013.
100. Nicholson P, Alfaadhel T, Keough V, **WEST M**, Geldenhuys L. Renal Biopsy Adequacy Rates: A Successful Interdepartmental Quality Improvement Activity. Canadian Society of Nephrology annual meeting, Montreal QC. April 24-28, 2013.
101. Van der Tol L, Biegstraaten M, Florquin S, Vogt L, van den Bergh Weerman MA,

- Hollak CEM, Hughes DA, Lachmann RH, Oliveira JP Ortiz AA, Svarstad E, Terryn W, Tondel C, Waldek S, Wanner C, **WEST ML**, Linthorst GE. Consensus Recommendation on Fabry Disease Diagnosis in Adult Patients with Kidney Disease. 10th Annual WORLD Symposium, San Diego CA USA. Feb. 11-13, 2014.
102. Smid B, van der Tol L, Cecchi F, Elliott P, Hughes D, Linthorst G, Timmermans J, Weidemann F, **WEST M**, Biegstraaten M, LeKanne Dit Deprez R, Florquin S, Postema P, van der Wal A, van den Bergh Weerman M, Hollak C. Consensus Recommendation on Fabry Disease Diagnosis in Adult Patients with Left Ventricular Hypertrophy. 10th Annual WORLD Symposium, San Diego CA USA. Feb. 11-13, 2014.
103. Arning E, Shen J-S, LeMoine K, Schiffmann R, **WEST M**, Bottiglieri T. Tetrahydrobiopterin in Fabry Disease. 10th Annual WORLD Symposium, San Diego CA USA. Feb. 11-13, 2014.
104. Khan A, Au BC, Taylor C, Rothe M, Bischof D, Sirrs S, Auray-Blais C, Rupar T, Prokopishyn N, Ohoski P, Huang J, Paul G, Benabid R, Viswanathan S, Morel C, Raiman J, Schambach A, **WEST M**, Keating A, Cornetta K, Foley R, Medin J. Pre-clinical patient cell mobilizations and transduction outcomes in preparation for a clinical trial application of Lentivirus-mediated gene therapy for Fabry disease. American Society of Gene and Cell Therapy 17th annual meeting, Washington DC USA. May 20-24, 2014.
105. Dyack S, **WEST M**, Sirrs S for the CFDI Investigators. Pediatric Fabry Disease in Canada: 5 year data from the CFDI. 10th Annual WORLD Symposium, San Diego CA USA. Feb. 11-13, 2014. Department of Medicine, Dalhousie University Annual Research Day, Halifax NS, May 1, 2014.
106. **WEST ML**, Bichet DG, Auray-Blais C, Casey R, Clarke JTR, LeMoine K. Outcomes of patients treated through the Canadian Fabry Disease Initiative (CFDI). Fabry Expert Lounge Meeting, Rome, Italy. March 21, 22, 2014. Department of Medicine, Dalhousie University Annual Research Day, Halifax NS, May 1, 2014.
107. Feriozzi S, Perrin A, **WEST M**, Nicholls K, Sunder-Plassmann G, Torras J, Neumann P, Cybulla M, on Behalf of the Fabry Outcome Survey Renal Working Group. Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors (ARB/ACE) Slow the Progression Of Nephropathy in Males With Fabry Disease. European Renal Association-European Dialysis and Transplant Association 51st Annual Meeting, Amsterdam, the Netherlands. May 31-June 3, 2014.
108. Cybulla M, **WEST M**, Nicholls K, Torras J, Neumann P, Sunder-Plassmann G, Feriozzi S, on behalf of the Fabry Outcome Survey Renal Working Group. Efficacy and Safety of Enzyme Replacement Therapy (ERT) in a Cohort of Kidney Transplant Recipients With Fabry Disease. European Renal Association-European Dialysis and Transplant Association 51st Annual Meeting, Amsterdam, the Netherlands. May 31-June 3, 2014.

109. Van Der Tol L, Biegstraaten M, Florquin S, Vogt L, Van Den Bergh Weerman MA, Hollak CEM, Hughes DA, Lachmann RH, Oliveira JP, Ortiz A, Svarstad E, Terry W, Tøndel C, Waldek S, Wanner C, **WEST ML**, Linthorst GE. Consensus Recommendation on Fabry Disease Diagnosis in Adult Patients With Kidney Disease. European Renal Association-European Dialysis and Transplant Association 51st Annual Meeting, Amsterdam, the Netherlands. May 31-June 3, 2014.
110. Wilson J-A, Soroka S, Wood M, Phillips M, Dill P, Gower T, Kleronomos-MacAlpine A, Sheehy N, Bartol C, Wile C, **WEST M**, Helyer L, Hart R, Lee M. Evaluation Plan for the 'Pathway for the Management of Elevated Parathyroid Hormone Levels in Dialysis Patients'. Capital District Health Authority Quality Summit, Halifax NS. May 29, 2014.
111. Beck M, Hughes D, Kampmann C, Mehta A, Pintos-Morell G, Ramaswami U, **WEST ML**, Wijatyk A, Giugliani R. The long-term effectiveness of agalsidase alfa in Fabry disease: a Fabry Outcome Survey analysis. SSIEM Annual Meeting. Innsbruck AT. Sept. 2-5, 2014. WORLD Symposium, Orlando, FLA USA. Feb. 10-13, 2015.
112. **WEST ML**, Bichet D, Casey R, Clarke JTF, Iwanochko M, Khan A, Sirrs S, Jayasinghe J, LeMoine K. Outcomes of patients over 65 in the Canadian Fabry Disease Initiative Study (CFDI). Department of Medicine Research Day, Dalhousie University, Halifax NS. March 26, 2015.
113. Carter MD, Castonguay MC, Offman SL, Gupta R, **WEST M**, Geldenhuys L. Aortic Dissection- a Complication of Fabry Disease? Department of Pathology Research Day, Dalhousie University, Halifax NS. May 1, 2015. Canadian Association of Pathology Meeting, Montreal QC, June 20-24, 2015.
114. **WEST ML**, Bichet DG, Khan A, Clarke JT, Sirrs S, Doucette S, Auray-Blais C, LeMoine K on behalf of the CFDI Investigators. Outcomes of Patients 65 and Older in the Canadian Fabry Disease Initiative Study. American Society of Nephrology Annual Meeting, San Diego CA USA, Nov. 6-9, 2015.
115. Najafian B, Tøndel C, Svarstad E, **WEST ML**, Mauer M. Podocyte Globotriaosylceramide (GL3) Accumulation in Fabry Disease Is Influenced by Age and Genotype. American Society of Nephrology Annual Meeting, San Diego CA USA, Nov. 6-9, 2015.
116. Beck M, Hughes D, Kampmann C, Bizjajeva S, Pintos-Morell G, Ramaswami U, **WEST M**, Giugliani R. Long-term outcomes with agalsidase alfa enzyme replacement therapy: analysis using deconstructed composite events. 12th Annual WORLD Symposium, San Diego CA, USA. Mar.1-4, 2016.
117. Ramaswami U, Beck M, Hughes D, Kampmann C, Bizjajeva S, Pintos-Morell G,

- WEST M**, Niu D-M, Nicholls K, Giugliani R. Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry Outcome Survey analysis. 12th Annual WORLD Symposium, San Diego CA, USA. Mar.1-4, 2016.
118. Giugliani R, Niu D-M, Ramaswami U, **WEST M**, Hughes D, Kampmann C, Pintos-Morell G, Nicholls K, Schenk J-M, Beck M. A fifteen-year perspective of the Fabry Outcome Survey (FOS). 12th Annual WORLD Symposium, San Diego CA, USA. Mar.1-4, 2016.
119. **WEST ML**, Bichet D, Casey R, Clarke JTF, Iwanochko M, Khan A, Sirrs S, Auray-Blais C, Doucette S, LeMoine K. for the CFDI Investigators Group. Switch of Enzyme Replacement Therapy (ERT) in the Canadian Fabry Disease Initiative Study (CFDI): Intermediate follow-up at 3 and a half years. Department of Medicine, Dalhousie University Annual Research Day, Pier 21, Halifax NS. Garrod Symposium 2016, Halifax NS May 19-21, 2016.
120. **WEST ML**, Bichet D, Casey R, Clarke JTF, Iwanochko M, Khan A, Sirrs S, Auray-Blais C, Doucette S, LeMoine K. for the CFDI Investigators Group. Canadian Fabry Disease Initiative Study (CFDI): 8 year Follow Up of Enzyme Replacement Therapy (ERT). Department of Medicine, Dalhousie University Annual Research Day, Pier 21, Halifax NS. Garrod Symposium 2016, Halifax NS May 19-21, 2016.
121. Sunder-Plassmann G, Cybulla M, Feriozzi S, Neumann P, Nicholls K, **WEST M**, Torras J, Gurevich A. Literature Review of the Prevalence of Fabry Disease in Dialysis, Kidney Transplant And Chronic Kidney Disease Populations. Society for the Study of Inborn Errors of Metabolism Annual Meeting, Rome It. Sept.6-9 2016.
122. Morel CF, Bichet D, Casey R, Clarke JTF, Iwanochko M, Khan A, Sirrs S, Auray-Blais C, Doucette S, LeMoine K, **WEST ML**. for the CFDI Investigators Group. Switch of Enzyme Replacement Therapy (ERT) in the Canadian Fabry Disease Initiative Study (CFDI). Society for the Study of Inborn Errors of Metabolism Annual Meeting, Rome It. Sept.6-9 2016.
123. Sirrs S, Bichet D, Casey R, Clarke JTF, Iwanochko M, Khan A, Auray-Blais C, Doucette S, LeMoine K, **WEST ML** for the CFDI Investigators Group. Canadian Fabry Disease Initiative Study (CFDI): 8 year Outcomes of Enzyme Replacement Therapy (ERT). Society for the Study of Inborn Errors of Metabolism Annual Meeting, Rome It. Sept.6-9 2016.
124. Shen J-S, Arning E, **WEST ML**, Day TS, Cheng SH, Schiffmann R, Bottiglieri T. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease. 13th Annual WORLD Symposium, San Diego CA, USA. Feb. 14-16, 2017.
125. **WEST ML**, Bichet DB, Iwanochko M, Khan A, Sirrs S, Whyte J, LeMoine K for the CFDI Investigators Group. Pharmacologic Chaperone Responsiveness in Canadian Patients with Fabry Disease. Department of Medicine Research Day, Dalhousie

University, Halifax NS. April 13, 2017. Garrod Symposium, Montreal QC. May 5-7, 2017.

126. Bedard K, Robinson C, Orr A, Gaston D, Yorke J, Nightingale M, Hu P, MacGillivray, Geldenhuys L, Dyack S, Hewlett T, **WEST M.** Putative association of a germline mutation in *HYOU1* with nephrosclerosis and end stage renal disease. Canadian College of Medical Geneticists Annual Meeting, Montreal QC. Apr. 30-May 3, 2017.

RESEARCH GRANTS RECEIVED

1987	Sandoz Inc. and Ontario Ministry of Health. Canadian multicentre cyclosporin trial in glomerulonephritis.	\$ 5,000
1988	Clinical Teaching and Research Fund, College of Medicine. University of Saskatchewan, Saskatoon. Study of potassium metabolism in diabetic ketoacidosis.	\$ 7,500
1989	Summer Student Research Project Stipend. College of Medicine. University of Saskatchewan, Saskatoon. Evaluation of glomerular hematuria by coulter counter and phase contrast microscopy. (Supervisor for Sharon Bailey.)	\$ 3,200
1988-1990	Kidney Foundation of Canada Research Grant. Renal tubular response to aldosterone during hyperglycemia.	\$35,000
1989-1990	Saskatchewan Health Research Board Establishment Grant. Renal potassium secretory response to exogenous mineralocorticoids in health and disease.	\$30,000
1990	Sandoz Inc. Canadian multicentre glomerulonephritis study.	\$2,000
1997	Jansen-Ortho Ltd. Erythropoietin delivery solution study	\$1,600
2000-02	Transkaryotic Therapies Inc. α -Galactosidase A replacement therapy in Fabry disease TKT-010 and 015	\$240,000
2001-04	Genzyme Corporation. Recombinant human α -galactosidase A and progression of renal disease and clinical events in Fabry disease Genzyme-008	\$145,819
2002-04	Screening for Fabry disease in ESRD patients in Nova Scotia CERCE grant Transkaryotic Therapies Inc.	\$129,664
2003-06	FIRE registry study Transkaryotic Therapies Inc.	\$28,086
2003-present	Genzyme Corporation. Fabry disease registry study	\$78,621

2004-06	Genzyme Corporation. Recombinant human α -Galactosidase A and progression of renal disease and clinical events in Fabry disease. Extension study, Genzyme-02503	\$12,778
2004	A Phase I-II pharmacokinetic-pharmacodynamic study of Replagal to assess the effects of alternative dose and regimen in patients with Fabry disease. TKT-027. Transkaryotic Therapies Inc.	\$27,174
2004	Fabry Disease: Lysosomal storage disease coordinator in Nova Scotia. CERCE grant Transkaryotic Therapies Inc.	\$66,000
2005	Fabry Disease: Lysosomal storage disease coordinator in Nova Scotia. CERCE grant Transkaryotic Therapies Inc.	\$66,000
2007	Fabry Disease Canadian Guidelines review Educational grants from Genzyme Corporation and Shire Human Genetic Therapies Inc.	\$11,600
2007	Canadian Fabry Disease Initiative Study Grant from Federal and Provincial Governments, Genzyme Corporation and Shire Human Genetic Therapies Inc.	\$1,194,275
2008	Canadian Fabry Disease Initiative Study Grant from Federal and Provincial Governments, Genzyme Corporation and Shire Human Genetic Therapies Inc.	\$874,716
2009	Fabry Disease: Lysosomal storage disease coordinator in Newfoundland. CERCE Grant Shire Human Genetic Therapies Inc.	\$71,000
2009	Canadian Fabry Disease Initiative Study Grant from Federal and Provincial Governments, Genzyme Corporation and Shire Human Genetic Therapies Inc.	\$874,716
2010	Fabry Disease Preceptorship. CERCE Grant, Shire Human Genetic Therapies Inc.	\$5,000
2010	Canadian Fabry Disease Initiative Study Grant from Provincial Governments, Genzyme Corporation and Shire Human Genetic Therapies Inc.	\$265,000
2010	Unrestricted Educational Grant, Shire Human Genetic Therapies Inc.	\$30,000
2011	Canadian Fabry Disease Initiative Study Grant from Provincial Governments, Genzyme Corporation and Shire	\$468,000

Human Genetic Therapies Inc.		
2011	Educational Grant, Shire Human Genetic Therapies Inc	\$5,000
2012	Canadian Fabry Disease Initiative Study Grant from Provincial Governments, Genzyme Corporation and Shire Human Genetic Therapies Inc.	\$468,000
2012	Fabry Disease Preceptorship. CERCE Grant, Shire Human Genetic Therapies Inc.	\$4,750
2012-17	Medin, Keating, Foley, WEST , Casey et al. FACTs Project: <u>F</u> abry Disease <u>C</u> linical Research and <u>T</u> herapeutics. Lentivector-Mediated Correction of Fabry Disease Targeting Mobilized Hematopoietic Stem/Progenitor Cells. CIHR	\$30,000
2011+	Orphan Diseases: Identifying Genes and Novel Therapeutics to Enhance Treatment (IGNITE) project:	\$30,000
2013	Canadian Fabry Disease Initiative Study Grant from Provincial Governments, Genzyme Corporation and Shire Human Genetic Therapies Inc.	\$391,611
2013	Grant from Shire Inc. for Newfoundland Fabry disease coordinator	\$40,000
2013	Grant from Genzyme Canada for X-inactivation study in Fabry disease heterozygotes	\$20,000
2014	Canadian Fabry Disease Initiative Study, Grant from Provincial Governments, Sanofi-Genzyme and Shire Inc.	\$1,000,000
2014	Grant from Shire Inc. for Newfoundland Fabry disease coordinator	\$75,000
2015	Canadian Fabry Disease Initiative Study, Grant from Provincial Governments, Sanofi-Genzyme and Shire Inc.	\$1,000,000
2016	Grant from Sanofi-Genzyme	\$50,000
2016	Canadian Fabry Disease Initiative Study, Grant from Provincial Governments, Genzyme, a Sanofi company and Shire Inc.	\$1,000,000
2016	Grant from Shire Inc. for Newfoundland Fabry disease coordinator	\$70,000
2017	Canadian Fabry Disease Initiative Study, Grant from Shire Inc.	\$800,000

2017 Canadian Fabry Disease Initiative Study, Grant from Amicus \$50,000

Total funding received
\$9,707,110

MANUSCRIPTS AND RESEARCH GRANTS REVIEWED

Clinical and Investigative Medicine	1993, 2002, 2003, 2005
Kidney Foundation of Canada Grant Competition.	1994, 1999
Canadian Medical Association Journal	1998, 2000, 2002, 2003, 2004, 2005
QEII Health Sciences Centre Research Foundation	2000
Journal of American Society of Nephrology	2007
Genetics in Medicine	2008, 2012, 2013, 2014, 2016, 2016, 2016
International Journal of Urology and Nephrology	2008
International Journal of Mass Spectrometry	2011
American Journal of Kidney Disease	2011
Pediatric Nephrology	2011
American Journal of Genetics	2011, 2012
Molecular Genetics and Metabolism	2013
Nephrology Dialysis Transplantation	2012
Nephron	2016, 2016
Orphanet Journal of Rare Diseases	2012, 2012, 2013, 2013, 2015
ZonMw – The Netherlands Organization for Health Research and Development. Rational Pharmacotherapy Program.	2012, 2013
Journal of Medical Genetics	2013, 2017
Clinical Investigation	2014
Clinical Genetics	2014
Shire Inc. Research Grant Program	2014
BMC Nephrology	2015, 2016
Journal of Inherited and Metabolic Disease	2015
Journal of Drug Assessment	2016
BMC Research Notes	2017

PROFESSIONAL PRACTICE

Saskatoon, Saskatchewan

1986-1990 Director, Dialysis Program, Royal University Hospital.
1986-1990 Clinical Nephrologist, Active Staff Royal University Hospital.
1986-1990 Consultant Nephrologist, St. Paul's Hospital and Saskatoon City Hospital.

Halifax, Nova Scotia

1990-present Clinical Nephrologist, Member, Renal Transplant Program, Active Staff, QEII
Health Sciences Centre, Capital District Health Authority, Halifax, NS
1990-present Consultant Nephrologist, IWK Health Centre for Children and Women, Halifax,
NS
2003 - 2008 Head, Division of Nephrology, Department of Medicine, Dalhousie University;

2003 - 2008 Nephrology Service Chief, QEII Health Sciences Centre, Capital District Health Authority, Halifax, NS

2010-present Consulting Nephrologist, Guysborough Antigonish Strait Health Authority, St. Hospital, Antigonish NS

CONSULTING WORK UNDERTAKEN

1998-present Medicolegal consultant

2001-2004 Medical consultant for Genzyme Corporation, Cambridge, MA, USA.

2001-2011 Medical consultant for Transkaryotic Therapies Inc. (now Shire Inc), Lexington MA, USA.

2014 Medical consultant for Amicus Therapeutics Inc

DEPARTMENTAL AND UNIVERSITY COMMITTEES

University of Saskatchewan: 1986-1990

Department of Medicine:

1986-90 JURSI Teachers Committee, Member

1989-90 Research Committee, Member

1987-90 Admission, Discharge and Utilization Committee, Member

1989-90 Liaison with Hospital Computerization Project

College of Medicine:

March 1989 MSc Thesis Committee, Department of Pharmacology - External Reviewer.

Dalhousie University: 1990-present

Department of Medicine:

1992-1996 Resident Research Committee, Member 1992-1996, Chair 1993-1996

1992-1998 Division of Nephrology, Quality Assurance Coordinator

1992-2002 Undergraduate Medical Education Committee, Member

1992-2002 Director, Undergraduate Medical Education, Division of Nephrology

1993 Departmental Review Committee for Division of General Medicine, Member

1993-1996 General Internal Medicine Residency Training Committee, Member

1993-1998 Division of Nephrology, Secretary

1993-1996 Research Committee, Member

1995-2003 Nephrology Post Graduate Training Program Committee, Member

1996-1999 Promotions Committee, Member

1997-2001 Resource Utilization Management Committee, Member

1997-2001 Grand Rounds Committee, Member

1998-2003 Nephrology Training Program, Director

2002 Executive Committee, Member at large

2001 Department of Medicine Working Group, Patient Information Services

2003-2005 Recognition of Members Contributions Committee Member

2003-2008 Executive Committee Member

2003-2008 Clinical Service Chiefs Committee, Member

2004-2005 Department of Medicine, Neurology Survey/Search Committee, Chair

2005-2008 Financial Management Committee, Member

2006-2009 Tariff Committee, Member
 2007-2009 Tariff Committee, Chair
 2008-2009 Educational Awards Committee, Member
 2010-2013 Nominating Committee, Member

Faculty of Medicine:

1992 Faculty of Medicine Admissions Interviewer
 1992- 2002 Med II COPS Curriculum Committee, Renal Component, Head
 1995-1999 Med II COPS Curriculum, Genitourinary, Gastrointestinal,
 Musculoskeletal Unit, Head
 1995-1999 Med II COPS Curriculum, Year Committee, Member
 1997 Med II COPS Curriculum, Promotions Committee, Member
 1996 Ad hoc Committee on Hypertension in the COPS Curriculum, Chair
 1995-present Dr. Allan D. Cohen/Kidney Foundation of Canada Nephrology Prize in
 Nephrology Committee, Member
 1997 Psychiatry Training Program, Internal Review, Surveyor
 1997-1998 Review and Search Committee for Associate Dean Undergraduate
 Medical Education, Member
 1998-2003 Postgraduate Medical Education Committee, Member
 1999 COPS Curriculum, Academic Progress Committee, Member
 2000-2002 COPS Curriculum, Unit Heads Committee, Member
 2003-2005 Scholarship and Awards Committee, Member
 2004-2005 Neurology Training Program, Internal Review, Surveyor
 2007-2008 Urology Department Head Search Committee, Member
 2009-present Dr. Allan D Cohen Award Committee, Member
 2010 Emergency Medicine Training Program, Internal Review, Surveyor
 2011-present Assistant Dean, Research-Clinical Trials
 2011-present Research Advisory Committee, Member
 2011-present Associate Dean's Research Advisory Committee, Member
 2013 Nov 13 Poster Judge, Interprofessional Health Research Day, Integrated Health
 Research Training Partnership
 2016-present Maritime Human Genomics Research Centre Executive Committee,
 Member
 2016-2017 Urology Department Survey and Search Committee, Chair
 2016-present Centre for Genomics Enhanced Medicine, Executive member

OTHER

1994-2002 Urology Clerkship Committee, Member
 1997 Selection Committee - Chief of Service Anatomical Pathology QEII
 Health Sciences Centre, Member

**PROFESSIONAL AND ASSOCIATION OFFICES AND COMMITTEE ACTIVITY
 OUTSIDE UNIVERSITY**

American College of Physicians, Atlantic Provinces Regional Council, Member, 1999-2011,
 Treasurer 2009-2011.

American College of Physicians, Fellow 1989, Member 1984-present.
 American Society of Nephrology, Member 1986-present
 Canadian Medical Association, Member 1979-present
 Canadian Society of Nephrology Member 1986-present;
 Annual Meeting Scientific Committee, Member, 1995-1999;
 Annual Meeting Scientific Committee, Chair, 1997-1998;
 Abstract Review Panel, Member, 1995-1999;
 Council Member, 1990-1999;
 Executive, 1994-1999;
 Treasurer, 1994-1995;
 Secretary, 1995-1996;
 President, 1996-1997;
 Past-President, 1997-1999;
 Organizer and Chair CME Workshop on Treatment of Idiopathic Glomerulonephritis
 September 1996 Halifax, NS;
 Organizer Annual Scientific Meeting CSN September 1997 Vancouver BC;
 Chair of Paper/Poster Discussion Sessions at CSN Annual Scientific Meeting, 1990-1999.

Doctors Nova Scotia (formerly Medical Society of Nova Scotia), Member 1990-present, Board
 Member, 1997-2000, Section of Nephrology, Member and Tariff Coordinator, 2007-
 present.

Halifax Medical Society, Member, 1991-1997

International Society of Nephrology, Member, 1986-present

Kidney Foundation of Canada, National Medical Advisory Board, Member, 1992-1996.
 Nova Scotia Branch, Medical Advisory Committee, Chairman, 1992-1996;
 Nova Scotia Branch Board Member, 1992-1996;
 Nova Scotia Branch Executive Committee Member, 1992-1996
 Nova Scotia Branch Dr. A.J. MacLeod Scholarship Committee, Member, 1992-1996.

Medical/Patient Care/Clinical Services Committee, Victoria General Hospital, Halifax, Member.
 1992-1995, Chair 1993-1995

Mortality and Morbidity Subcommittee of Clinical Appraisal Committee, Victoria General
 Hospital, Halifax, Member, 1990-1992

Nova Scotia Society of Internal Medicine, Member, 1990-present
 Council Member, 1996-2002
 President, 1997-2000
 Past-president 2000-2002

Pharmacy Continuous Quality Improvement Pilot Project, Victoria General Hospital, Medical
 Consultant, 1992.

Physicians For a Smoke Free Canada, Member, 1990-present.

President's Task Force on Physician Continuous Quality Improvement, Victoria General
 Hospital, Halifax, Member, 1993.

Royal College of Physicians and Surgeons of Canada, Fellow 1984-present;
 MOCOMP/MOCERT Credit Assessor, 1997-2005;
 Annual Meeting Scientific Committee, Member, 1996-1997;
 Nephrology Subspecialty Committee, Member, 1997-2003;
 Accreditation Committee, Member 2002-2007;

Chair, Documents Subcommittee, Accreditation Committee 2004-2007;
Accreditation Surveyor: University of Saskatchewan, Saskatoon, September 21-25, 2003;
University of Calgary Special Surveys Nephrology and Perinatology/Neonatology, May
18-19, 2005; University of Western Ontario, London ON, Oct. 16-19, 2006; University of
Calgary, Calgary AB Feb. 22-26, 2009.

PUBLIC AND COMMUNITY CONTRIBUTIONS

Third Avenue United Church, Saskatoon, SK, Member of Official Board, Session, and Ministry
and Personnel Committee; Chairman, Pastoral Relations Committee, 1986-1990.

Queen's University, Kingston ON 1991 and 2005 Alumni Achievement Award Committee,
Member.

St. Matthew's United Church, Halifax, NS, Member of Official Board and Session, 1994-2005,
Elder, 1994-2005.

United Church of Canada Ministry Committee, Dalhousie University, Halifax, NS, Member,
1999-2002.

Old Burying Ground Foundation Board, Halifax, NS, Member, 2001-2004.

Fabry Disease Public Information Meetings in Atlantic Canada:

Bridgewater NS. July 2001

Chester NS. Feb. 2002

Antigonish NS. May 2003

Lunenburg NS. Dec. 2003

Liverpool NS. Dec. 2004

Kidney Foundation of Canada Nova Scotia Branch, Halifax NS. May 2005

Mahone Bay NS. June 2005

Canadian Fabry Association National Meeting, Halifax NS. May 2006

Mahone Bay NS. April 14, 2007

Oak Island Resort, Martins River NS. Nov. 15, 2008

East Chester NS. May 15, 2010

Mahone Bay NS. March 26, 2011

Rocky Harbour NL. Sept. 21, 2011

Fabulous Females of Fabry Disease. Oak Island Resort, Martins River NS. Sept 27,28,
2014

Mahone Bay NS. Sept. 26, 2015

PERSONAL

1995-1999 Volunteer canvasser for Kidney Foundation of Canada annual March Fundraising
Drive

OTHER

Apr 2005-Apr 2006 Board Member, Fabry International Research Initiative Registry,
Cambridge MA, USA.

April 2006-present Board Member, Fabry Outcomes Survey Registry, Eysens, Switzerland.

April 2006 Co-Chair, Fabry Outcomes Survey session, 6th International Symposium
on Lysosomal Storage Disease, Stockholm, Sweden.

May 2006-2008 Chair, Renal Working Group, Fabry Outcomes Survey Registry,

Stockholm, Sweden. Member 2006-present

2006-present Canadian Fabry Disease Initiative Study, Chair of Scientific Committee and Principal Investigator

Feb 10-11, 2007 Organizer and Chair: Canadian Fabry Disease Treatment Guidelines Conference, Toronto ON.

June 6-8, 2008 Organizer and Co-chair: Advances in the Treatment of Lysosomal Storage Disorders Conference, Halifax, NS.

June 6-8, 2008 Organizer and Chair: Canadian Fabry Disease Treatment Guidelines Conference, Halifax, NS. ½ day

April 24-25, 2009 Member, Scientific Program Committee, 9th International Symposium on Lysosomal Storage Diseases, Frankfurt Germany. 2 days

May 27-28, 2009 Member, Scientific Program Committee, Plenary Session Co-chair and Chair of Workshop on Enzyme Replacement Therapy Dose, Fabry Nephropathy: Satellite Symposium of the World Congress of Nephrology, Bergamo Italy. 2 days

June 6, 2008 Organizer and Chair of Annual CFDI Scientific Meeting, Sheraton Four Points Hotel Halifax NS.

June 6, 2008 Organizer and Chair of Annual Canadian Fabry Disease Treatment Guidelines Review Meeting, Sheraton Four Points Hotel, Halifax NS.

June 3, 2009 Organizer and Chair of Annual CFDI Scientific Meeting, Queen Elizabeth II Hotel, Montreal QC.

June 3, 2009 Organizer and Chair of Annual Canadian Fabry Disease Treatment Guidelines Review Meeting, Queen Elizabeth II Hotel, Montreal QC.

Sept. 18, 2009 Organizer and presenter for Preceptorship in Fabry Disease, QE II Health Sciences Centre, Halifax NS; Drs. C. Laurenco, R. Martin.

May 7, 2010 Organizer and Chair of Annual Canadian Fabry Disease Treatment Guidelines Review Meeting, Park Hyatt Hotel, Toronto ON.

May 22, 2010 Session Chair, Symposium on Anderson Fabry Disease and the Heart, Cardiomyopathy Association, London UK.

June 2, 2010 Organizer and Chair of Annual Canadian Fabry Disease Initiative Study Scientific Meeting, Chateau Frontenac, Quebec City QC.

June 17-18, 2010 Organizer and presenter for Preceptorship in Fabry Disease, QE II Health Sciences Centre, Halifax NS; Dr. S. Swati, Dr. O. Goker-Alpan

2010-2014 Member, Data Safety and Monitoring Committee, AT1001-010 trial A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Amicus Therapeutics Inc.

Dec. 3-4, 2010 Member, Abstract Awards Committee, International Workshop on Lysosomal Storage Diseases, Prague, Czech Republic.

2011 to present Executive Member, Fabry Outcomes Survey Registry, Eysins, Switzerland.

Apr. 2, 2011 Session Chair, International Symposium on Lysosomal Storage Diseases, Madrid, Spain.

April 12-14, 2011 Meeting Co-chair, Member Organizing Committee, Session Co-chair,

Workshop Chair on ERT: Current Status of Trials and Future Directions at Fabry Nephropathy: Biomarkers, Progression and Treatment Opportunities, Satellite Meeting to the World Congress of Nephrology, Vancouver BC.

May 31, 2011 Organizer and Chair of Annual Canadian Fabry Disease Treatment Guidelines Review Meeting, Vancouver BC.

June 1, 2011 Organizer and Chair of Annual Canadian Fabry Disease Initiative Study Scientific Meeting, Vancouver BC.

2011-2014 Member, Data Safety and Monitoring Committee, AT1001-012 trial A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations Who Are Also Receiving Enzyme Replacement Therapy, Amicus Therapeutics Inc.

June 6, 2012 Organizer and Chair of Canadian Fabry Disease Treatment Guidelines Committee Meeting, Halifax NS.

June 7, 2012 Organizer and Chair of Canadian Fabry Disease Initiative Study Annual Meeting, Halifax NS.

June 8, 2012 Chair of Shire Advisory Board Meeting: Exploring the current and future state of ERT in Fabry Disease, Halifax NS.

June 21,22, 2012 Organizer and presenter for Preceptorship in Fabry Disease, QE II Health Sciences Centre, Halifax NS; Dr. Tze-Wah Kao, Dr. Chih-Chan Lin, Dr. Wen-Chung Yu, Dr. Carmen Enciu, D. Hollihan RN.

Sept. 9, 2012 Sabbatical leave, Division of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

-Mar. 8, 2013

May 10, 2013 Organizer and Chair, Canadian Fabry Disease Treatment Guidelines Committee Meeting, Montreal QC.

May 11, 2013 Organizer and Chair, Canadian Fabry Disease Initiative Study Annual Scientific Meeting, Montreal QC.

June 4-5, 2013 Meeting Co-chair, Member Organizing Committee, Session Chair, Third Update on Fabry Nephropathy. Biomarkers, Progression and Treatment Opportunities. Hong Kong, China.

2014-present Member, Data Safety and Monitoring Committee, AT1001-014 trial, Amicus Therapeutics Inc.

May 16-17, 2014 Chair, three Workshops on Management of the Manifestations of Fabry Kidney Disease, Fabry Masterclass IV Meeting, Prague, CZ.

June 20, 2014 Chair and Organizer, Scientific Committee Meeting, CFI Study, Vancouver BC.

June 21, 2014 Chair and Organizer, Canadian Fabry Disease Treatment Guidelines Committee Meeting, Vancouver BC.

June 21, 2014 Chair and Organizer, Canadian Fabry Disease Treatment Initiative Study Annual Meeting, Vancouver BC.

May 7, 2015 Chair, Fabry Session, LSD Club Annual Meeting, Rimrock Hotel Banff AB.

June 1-2, 2015	Member, Organizing Committee, 4th Symposium on Fabry Nephropathy, a Satellite meeting of the European Renal Association/European Dialysis and Transplant Association. Manchester UK.
June 20, 2015	Chair and Organizer, Canadian Fabry Disease Treatment Guidelines Committee Meeting, Calgary AB.
Oct. 15-17, 2015	Member, Organizing Committee. Group1: Screening & Diagnosis Discussion Leader. KDIGO Controversies Conference on Diagnosis and Management of Patients with Fabry Nephropathy, Dublin IE.
Oct. 23,24, 2015	Member, Scientific Committee, European Symposium on Lysosomal Storage Diseases, Barcelona, SP
May 14, 2016	Session Chair, CKD Classification, Canadian Society of Nephrology Annual Meeting Halifax NS
May 18, 2016	Member, Canadian Fabry Disease Treatment Guidelines Review Committee Annual Meeting, Halifax NS.
May 18, 2016	Organizer and Chair of Annual CFDI Study Scientific Meeting, Halifax, NS.
May 19, 2016	Organizer and Chair Fabry Disease Symposium. Highlights and Updates on Fabry Disease: Adult and Pediatric Outcomes. Garrod Symposium 2016, Halifax NS.
June 13, 2016	External Reviewer, Institutional Review Board, King Khalid Medical City Center for Health Research, Dammam, Saudi Arabia.
Nov. 12, 2016 to present	Executive Member, Centre for Genomic Enhanced Medicine, Faculty of Medicine, Dalhousie University, Halifax NS.
April 25-27,2017	Member, Organizing Committee, Session CoChair, 5th Symposium on Fabry Nephropathy, a Satellite meeting of the World Congress of Nephrology, Mexico City, Mexico.

CONTINUING PROFESSIONAL DEVELOPMENT

<u>Date</u>	<u>Course/Meeting</u>	<u>Time</u>
April 1982	American College of Physicians Annual Meeting, Philadelphia, PA USA.	4 days
April 1982	American College of Physicians Post Graduate Course: Diabetes Mellitus, Philadelphia, PA USA.	2 days
April 1983	American College of Physicians Annual Meeting, San Francisco, CA USA	4 days
April 1983	American College of Physicians Post Graduate Course: Emergency Management of the Critically Ill Patient, San Francisco, CA USA	2 days
Dec. 1983	American Society of Nephrology Annual Meeting, Washington, DC USA	4 days

Sept 1984	Royal College of Physicians and Surgeons of Canada Meeting, Montreal, QC	4 days
Dec. 1984	American Society of Nephrology Annual Meeting, Washington, DC USA	4 days
Apr. 19-20, 1985	American College of Physicians Regional Meeting, Toronto, ON	1½ days
April 1985	Berliner Symposium on Potassium Physiology, Yale University, New Haven, CT USA	2 days
May 23-24, 1985	International Symposium on Geriatric Nephrology Nephrology, Toronto, ON	2 days
June 1985	Canadian Federation of Biological Societies 28th Annual Meeting, Toronto, ON	5 days
Sept 1985	Royal College of Physicians and Surgeons of Canada Annual Meeting, Vancouver, BC	4 days
Feb. 28- Mar. 1, 1986	American College of Physicians Regional Meeting, Toronto, ON	1½ days
May 1986	4th Annual Membrane Transport Workshop, University of Toronto, Toronto, ON	1 day
Sept 1986	Royal College of Physicians and Surgeons of Canada Annual Meeting, Toronto, ON	4 days
Dec. 1986	American Society of Nephrology Annual Meeting, Washington, DC USA	4 days
Sept 1986	Royal College of Physicians & Surgeons of Canada Annual Meeting, Winnipeg, MB	4 days
Mar. 3-6, 1988	American College of Physicians Annual Meeting, New York, NY USA	4 days
Mar. 17-18, 1988	National Kidney Foundation Symposium on IgA Nephropathy Washington, DC USA	2 days
Apr. 12, 1988	Presentation: Treating the Elderly Hypertensive, Saskatoon, SK, Dr. H.R. Black	1 hr

Oct. 6, 1988	Symposium on Hyperlipidemia, Vancouver, BC	1 day
Dec. 10-11, 1988	National Kidney Foundation Annual Meeting, San Antonio, TX USA	2 days
Dec. 11-14, 1988	American Society of Nephrology Annual Meeting, San Antonio, TX USA	4 days
May 23-25, 1989	American Society for Artificial Internal Organs Annual Meeting, Dallas, TX USA	3 days
Sept. 22-25, 1989	Royal College of Physicians and Surgeons of Canada Annual Meeting, Edmonton, AB	4 days
Oct. 21, 1989	Medical Alumni Day, Queen's University, Kingston, ON	½ day
Feb. 8-10, 1990	10th Annual Peritoneal Dialysis Conference, Dallas, TX USA	3 days
May 25-26, 1990	American College of Physicians, Regional Meeting, Saskatchewan - Manitoba, Saskatoon, SK	2 days
Sept. 14-17, 1990	Royal College of Physicians and Surgeons of Canada Annual Meeting, Toronto, ON	4 days
Nov. 16, 1990	Workshop on Evaluation, Dept. of Medicine, Dalhousie University, Halifax, NS	1 day
Nov 30-Dec 2, 1990	National Kidney Foundation Annual Meeting, Washington, DC USA	2½ days
Dec. 2-5, 1990	American Society of Nephrology Annual Meeting, Washington, DC USA	3½ days
Apr. 9-10, 1991	Critical Care Medicine 1991 Review Course, American College of Physicians, New Orleans, LA USA	2 days
Apr. 11-14, 1991	American College of Physicians Annual Meeting, New Orleans, LA USA	3½ days
Oct. 16-19, 1991	Renal Biopsy in Medical Diseases of the Kidney, College of Physicians and Surgeons, Columbia University, New York, NY USA.	4 days
Feb. 19-21, 1992	Twelfth Annual Conference on Peritoneal Dialysis, Seattle, WA USA	2½ days

Mar. 31, 1992	Canadian Transplant Society Teleconference. Role of Infection and Immunosuppression in the Development of Lymphoproliferative Disorders.	1 hr
Sept. 11-14, 1992	Royal College of Physicians and Surgeons of Canada Annual Meeting, Ottawa, ON	4 days
Oct. 1-4, 1992	Sixth Congress of the International Society for Peritoneal Dialysis Thessaloniki, Greece.	4 days
Nov. 15-18, 1992	American Society of Nephrology Annual Meeting, Baltimore, MD USA	4 days
Sept. 9-13, 1993	Royal College of Physicians and Surgeons of Canada Annual Meeting, Vancouver, BC	4 days
Mar. 4-5, 1994	Department of Medicine Education Workshop, "Redefining the Medicine Clerkship 1994 and Beyond", Halifax, NS	2 days
Sept. 15-18, 1994	Royal College of Physicians and Surgeons of Canada Annual Meeting, Toronto, ON	3 days
Oct. 26-29, 1994	American Society of Nephrology Annual Meeting, Orlando, FL USA	4 days
Feb. 1995	Fourteenth Annual Conference on Peritoneal Dialysis, Baltimore, MD USA	3 days
Sept. 1995	Royal College of Physicians and Surgeons of Canada Annual Meeting, Montreal, QC.	3 days
Feb. 21-23, 1996	16th Annual Conference on Peritoneal Dialysis, Seattle, WA, USA	3 days
Sept. 26, 1996	Canadian Society of Nephrology 2nd Annual Workshop, Treatment of Idiopathic Glomerulonephritis, Halifax, NS	1 day
Sept. 26-29, 1996	Royal College of Physicians and Surgeons of Canada Annual Meeting, Halifax, NS	4 days
Oct. 5, 1996	Dalhousie University, Department of Medicine Workshop, Teaching the Teachers: New Approaches to Small and Large Groups, Halifax, NS	1 day
Nov. 2-5, 1996	American Society of Nephrology Annual Meeting, New Orleans,	4 days

LA USA

Apr.30- May 2, 1997	The Royal College of Physicians and Surgeons of Canada 4th Annual Maintenance of Competence Conference: Strategies for Recruiting specialists into MOCOMP, Ottawa, ON	3 days
June 12-14, 1997	Medical Society of Nova Scotia Annual Meeting, Halifax, NS	3 days
Sept.25-28, 1997	Royal College of Physicians and Surgeons of Canada, Annual Meeting, Vancouver, BC.	5 days
Sept. 24, 1997	Canadian Society of Nephrology 3rd Annual CME Workshop, Diabetic Nephropathy, Vancouver, BC	1 day
Nov. 17, 1997	Workshop on Writing Effective Consultation Notes and Letters, QEII Health Sciences Centre, Halifax, NS	½ day
Feb 25-27, 1998	Annual Conference on Peritoneal Dialysis, Nashville, TN, USA	3 days
April 2, 1998	The Role of Diagnostic Radiology in the Management of Vascular Access in Hemodialysis and Complications and Management of Central Venous Hemodialysis Catheters, Dr. Andrew Common Halifax, NS	2 hrs
May 21-23, 1998	Medical Society of Nova Scotia Annual Meeting, Halifax, NS	3 days
April 24, 1998	Transplant Atlantic Scientific Meeting, QEII Health Sciences, Halifax, NS	1 day
Sept. 23-25, 1998	Royal College of Physicians and Surgeons of Canada, 1998 Conjoint Conference on Medical Education, Toronto, ON	2 days
Sept. 25-27, 1998	Royal College of Physicians and Surgeons of Canada, Annual Meeting, Toronto, ON	3 days
Sept. 24, 1998	Canadian Society of Nephrology Annual Meeting and CSN Clinical Course “Progressive Renal Disease Management: How Effective Are We?”, Toronto, ON	4 days
Oct. 23, 1998	Dalhousie University: Communication Skills Workshop, QE II Health Sciences Centre, Halifax, NS	1day
Nov. 14, 1998	CANNT. Atlantic Regional Symposium “A Time to Review, A Time to Look Ahead”, QE II Health Sciences Centre, Halifax, NS	1day

Nov. 25, 1998	Dalhousie University, Department of Medicine, Teach The Teachers Workshop for Physicians ‘Survival Skills’. QE II Health Sciences Centre, Halifax, NS	1 day
Dec. 3-4, 1998	Royal College of Physicians and Surgeons of Canada Workshop for New Surveyors and Specialty Committee Chairs, Ottawa, ON	2 days
Jan. 28, 1999	Department of Medicine Research Evening, Citadel Inn, Halifax, NS	3½ hrs
Feb. 22-23, 1999	Tutor Training Workshop, Dalhousie University, Halifax NS	2 days
April 20, 1999	What’s New in Focal Segmental Glomerulonephritis? Dr. Daniel C. Cattran, QEII HSC, Halifax, NS	1 hr
Sept. 23-24, 1999	5 th Annual Conference on Residency Education, RCPSC, Montreal, QC	2 days
Sept. 30-Oct. 2, 1999	Transplant Atlantic Annual Meeting, Halifax, NS	3 days
Nov. 1-8, 1999	American Society of Nephrology Annual Meeting, Miami, FL USA	8 days
Nov. 17, 1999	Multiple Choice Question Workshop, Department of Medicine Dalhousie University, Halifax NS	2 hrs
Jan. 12, 2000	Dalhousie University, Department of Medicine, Teach the Teachers Workshop, Halifax, NS	4 hrs
Jan. 28, 2000	Communication Skills Workshop, Division of Medical Education and Postgraduate Medical Education, Faculty of Medicine, Dalhousie University, Halifax, NS	8 hrs
Mar 3-7, 2000	Canadian Society of Nephrology Annual Meeting, Montreal, QC	5 days
May 13, 2000	Valley Spring Refresher, Nova Scotia Society of Internal Medicine Annual Meeting, Kentville, NS	5 hrs
Nov 25, 2000	Doctor’s Health in the New Millenium, Dalhousie University Faculty of Medicine, Halifax, NS	3 hrs
Nov 9, 2000	3 rd Teach the Teachers Workshop, Continuing Medical Education Department of Medicine, Dalhousie University, Halifax, NS	3 hrs
Feb 7-8, 2001	Fabry Disease International Research Exchange, Orlando, FL USA	2 days

Mar 8, 2001	Faculty Development Workshop Registration, Dalhousie University, Halifax, NS	3 hrs
Apr 27-28, 2001	5 th Atlantic Pre-Dialysis Conference “Building Partnerships”, MOMENTUM, Enriching Predialysis Education, Halifax, NS	7 hrs
May 10, 2001	Palm Pilot Workshop “Using the Palm Handheld Computer in Daily Medical Practice”, Dalhousie University, Halifax, NS	2 hrs
May 24, 2001	Teach the Teachers Workshop – Multimedia and You!, CME, Department of Medicine, Dalhousie University, Halifax, NS	3 hrs
Jun 9-10, 2001	Cardio-Renal Protection: Focus on the Prime Study Program, Bristol-Myers Squibb, Sanofi-Synthelabo, Cardigan, PE	8 hrs
June 26-29, 2001	International Society for Peritoneal Dialysis Meeting, Montreal, QC	4 days
July 28, 2001	Nova Scotia Society of Internal Medicine Annual Meeting, Frontier Therapy for the Brave and Smart – Novel Therapies We Can All Use, Wolfville, NS	1½ days
Aug 13-14, 2001	Web CT Workshop, Dalhousie University, Halifax, NS	2 days
Oct 4-5, 2001	Transplant Atlantic 2001, Royal Bank Auditorium, QEII Health Sciences Centre, Halifax, NS	2 days
Nov 17, 2001	2001 Gaucher/LSD Club Annual Meeting, Toronto, ON	5½ hrs
Nov 23-24, 2001	Manpower Conference 2001, Department of Medicine, Dalhousie University/ QEII Health Sciences Centre, Halifax, NS	1½ days
Mar 17-20, 2002	Canadian Society of Nephrology Annual Meeting, Ottawa, ON	3½ days
April 4, 2002	Resident Research Evening, Department of Medicine, Dalhousie University Halifax, NS	3 hrs
Apr 26-27, 2002	2 nd International Symposium on Lysosomal Storage Diseases, Cannes, France	2 days
Sept 19, 2002	Royal College of Physicians and Surgeons of Canada Workshop on Program Accreditation, Ottawa, ON	1 day
Oct 2-4, 2002	Transplant Atlantic, 2002, Royal Bank Theatre, QEII HSC, Halifax, NS	2 days

Oct. 15-19, 2002	American Society of Human Genetics Annual Meeting, Baltimore, MD USA	4 days
Oct 30-Nov 4, 2002	American Society of Nephrology Annual Meeting, Philadelphia, PA USA	4 days
Nov 7, 2002	Faculty Research Day, Department of Medicine, Halifax, NS	1 day
Nov 16, 2002.	Canadian LSD Club Meeting, Vancouver, BC	1 day
Apr 2-4, 2003	12 th Congress Argentina de Nefrologia, San Miguel de Tucuman, Argentina	3 days
Apr 17, 2003	Department of Medicine Resident Research Day, Halifax, NS	1 day
May 16-17, 2003	3 rd International Symposium on Lysosomal Storage Disease, Santiago de Compostela, Spain	2 days
Sept 22-24, 2003	Fabry Disease Preceptorship, Mt. Sinai Medical Centre, New York, NY and Genzyme Corporation, Cambridge, MA USA	3 days
Oct 1-3, 2003	Transplant Atlantic, Royal Bank Theatre, QE II Health Sciences Centre, Halifax, NS	3 days
Oct. 10-11, 2003	Workshop on Fabry Disease, Palma de Mallorca, Spain	2 days
Nov. 27-29, 2003	Principles & Practice of Medicine “Medicine Matters”, Halifax, NS	3 days
Feb. 9-11, 2004	24 th Annual Conference on Peritoneal Dialysis, San Antonio, TX, USA	3 days
April 23, 24 2004	4th International Symposium on Lysosomal Storage Disease, Seville, Spain	2 days
May 29-31, 2004	Canadian Society of Nephrology Annual Meeting, Toronto ON	3 days
May 27, 28, 2004	TKT Canadian Symposium on Fabry Disease, Toronto, ON	2 days
July 30, 2004	Physiology of Peritoneal Ultrafiltration, Dr. Karl Nolph Emeritus Professor, University of Missouri, QEII HSC, Halifax NS	2 hrs
Oct. 6-8, 2004	Transplant Atlantic Meeting 2004, QEII HSC, Halifax, NS	2 days

Oct. 25, 2004	LSD Club Meeting. Toronto, ON	1 day
Oct. 26, 2004	Fabry Phase IV: AGAL-008-00 Investigator Meeting, Toronto, ON	2 hrs
Oct. 26-29, 2004	American Society of Human Genetics Annual Meeting, Toronto ON.	4 days
Oct. 26, 2004	FIRE Registry Annual Meeting. Toronto, ON	½ day
Oct. 28, 2004	Fabry Disease: The world wide experience with Replagal™ (agalsidase alfa), Toronto, ON	3 hrs
Dec. 2-4, 2004	Principles & Practice of Medicine. Medicine Matters II. Department of Medicine Dalhousie University Halifax, NS	2½ days
April 15, 16 2005	5th International Symposium on Lysosomal Storage Disease, Valencia, Spain	2 days
May 21, 2005	9 th Annual LSD Registries Meeting, Phoenix, AZ USA	1 day
June 24, 2005	FIRE Investigator Meeting, Boston, MA USA	1 day
Sept. 9, 2005	Health Canada Policy Conference on Expensive Drugs for Rare Diseases, Toronto, ON	1 day
Sept. 17-8, 2005	Advances in the Treatment of Fabry Disease, Toronto, ON	2 days
Oct. 6-7, 2005	Transplant Atlantic Annual Meeting, Halifax, NS	2 days
Oct. 12-22, 2005	6 th European Round Table on Fabry Disease, Geneva, Switzerland	2 days
Nov. 3, 2005	Department of Medicine Research Evening, Halifax, NS	3 hrs
Nov. 10-13, 2005	American Society of Nephrology Annual Meeting, Philadelphia, PA USA	3½ days
Feb. 1, 2006	Fabry Disease Renal Biopsy Working Group Meeting, Paris, France	1 day
Mar. 10, 2006	Fabry Physician Advisory Panel Meeting, Boston, MA USA	1 day
April 28-29, 2006	6th International Symposium on Lysosomal Storage Disease, Stockholm, Sweden	2 days
May 11, 2006	Garrod Association of Canada Annual Meeting, Halifax, NS	1 day

May 12, 2006	Canadian Fabry Association Annual Meeting, Halifax, NS	1 day
May 27-29, 2006	Canadian Society of Nephrology Annual Meeting, Quebec City QC	3 days
June 1, 2006	Fabry Disease Renal Biopsy Working Group Meeting, Manchester, UK	1 day
Oct. 20-22, 2006	Advances in the Treatment of Fabry Disease, Vancouver, BC	2 days
Oct. 25, 2006	Renal Working Group Meeting, Fabry Outcomes Survey Registry Frankfurt, Germany	1 day
Oct. 27-28, 2006	7 th European Round Table on Fabry Disease, Barcelona, Spain	1½ days
Nov. 10-11, 2006	International Workshop on Lysosomal Storage Disorders, Budapest, Hungary	2 days
Nov. 16-19, 2006	American Society of Nephrology Annual Meeting, San Diego CA USA	3½ days
Dec. 7-9, 2006	3 rd Annual WORLD Symposium, Orlando, FL USA	3 days
Jan. 27, 2007	5 th FOS Investigator Meeting, Frankfurt, Germany	1 day
February 10, 2007	Canadian Fabry Disease Guidelines Meeting, Toronto, ON	1 day
April 27,28 2007	7th International Symposium on Lysosomal Storage Diseases, Rome, Italy	2 days
May 11-13, 2007	10 th Annual Nephrology New Brunswick Forum, Managing Chronic Kidney Disease: Home is where the patients should be. St Andrews, NB.	2½ days
May 25-27, 2007	Canadian Society of Nephrology Annual Meeting, Halifax, NS	3 days
Sept. 12, 2007	Health Canada Policy Conference on Expensive Drugs for Rare Diseases, Toronto, ON	1 day
Sept 28-30, 2007	Prevention in Renal Disease Conference, Toronto, ON	2½ days
Mar. 16, 2008	CIHR International Oversight Committee Meeting, CFDI study Toronto ON	½ day

Mar. 29, 2008	Organ Donation After Cardiocirculatory Death in Atlantic Canada Halifax, NS	1 day
April 5, 2008	Moving On: Transition of Youth from Pediatric to Adult Health Care. Dalhousie University, Halifax, NS.	1 day
April 9, 2008	Pathology Grand Rounds, QE II Health Sciences Centre, Halifax NS	1 hr
April 17-19, 2008	8th International Symposium on Lysosomal Storage Diseases, Paris, France	2½ days
May 1, 2008	Lysosomal Storage Disease Club Meeting, Toronto ON	1 day
May 2-3, 2008	Garrod Association Meeting, Toronto ON	1½ days
June 5, 2008	Canadian Fabry Disease Initiative Study Annual Meeting, Halifax, NS	½ day
June 5, 2008	Canadian Fabry Disease Treatment Guidelines Committee Meeting Halifax, NS	½ day
June 6-8, 2008	Advances in the Treatment of Lysosomal Storage Disorders, Halifax, NS	2½ days
Nov. 7-8, 2008	International Workshop on Lysosomal Storage Disorders, Lisbon, Portugal	2 days
Nov. 8, 2008	Canadian Fabry Association Meeting, Oak Island Inn, Martins River, NS	½ day
Nov 12-15, 2008	American Society of Human Genetics Annual Meeting, Philadelphia, PA, USA	4 days
Dec. 4, 2008	Annual Dalhousie University Refresher CME Meeting, Halifax NS	1 day
Dec 5, 2008	Global Fabry Disease Advisory Board Meeting, Boston MA, USA	1 day
Apr. 22, 2009	Global Fabry Disease Advisory Board Meeting, Frankfurt Germany	1 day
Apr. 24-25, 2009	9 th International Symposium on Lysosomal Storage Diseases, Frankfurt, Germany	2 days
May 22-26, 2009	World Congress of Nephrology, Milan, Italy	4 days
May 27-28, 2009	Satellite Symposium: Focus on Fabry Nephropathy. Biomarkers,	2 days

Progression and Disease Severity, Bergamo, Italy.

June 3, 2009	Canadian Fabry Disease Guidelines Annual Review, Queen Elizabeth II Hotel, Montreal QC.	½ day
\June 3, 2009	Canadian Fabry Disease Initiative Study, Annual Meeting, Queen Elizabeth II Hotel, Montreal QC.	½ day
Sept. 19, 2009	Canadian Fabry Association, National Meeting, Halifax, NS	1 day
Oct. 2, 2009	Gairdner Foundation Symposium. Genetics and the Future of Medicine: Opportunities for Atlantic Canada. Halifax, NS.	1 day
Oct. 16-17, 2009	10 th European Round Table on Fabry Disease, Prague, Czech Republic.	1½ days
Oct. 29-Nov. 1, 2009	American Society of Nephrology annual meeting San Diego, CA USA.	3½ days
Nov. 4, 2009	Global Fabry Disease Advisory Board Meeting, Barcelona, Spain.	1 day
Nov. 7-8, 2009	International Workshop on Lysosomal Storage Disorders, Barcelona, Spain.	2 days
Feb. 10-12, 2010	6 th Annual WORLD Symposium 2010, Miami, FL USA.	3 days
Mar. 23, 2010	Fabry Expert Advisory Group Meeting, London, UK	1 day
May 6, 2010	Advances in Lysosomal Storage Diseases, Toronto, ON	1 day
May 7, 2010	FOS Canada Review Meeting, Toronto, ON	½ day
May 7, 2010	Canadian Fabry Disease Treatment Guidelines Review, Toronto, ON	½day
May 22, 2010	Symposium on Anderson Fabry Disease and the Heart, Cardiomyopathy Association, London, UK.	1 day
June 2, 2010	Canadian Fabry Disease Initiative Annual Meeting, Quebec City, QC	1day
June 3-4, 2010	LSD Club Meeting, Quebec City, QC	1½ days
Sept 9-10, 2010	Fabry Disease Masterclass Meeting, Salvador, Bahia Brazil.	1½ days
Oct. 15-16, 2010	11 th European Round Table Meeting on Fabry Disease, Istanbul, Turkey	2 days

Nov 16-21, 2010	American Society of Nephrology Annual Meeting, Denver USA	4½ days
Dec. 3,4, 2010	International Workshop on Lysosomal Storage Disorders, Prague, Czech Republic	2 days
Mar. 31, 2011	Global Fabry Disease Advisory Board Meeting, Madrid, Spain	1 day
April 1-2, 2011	International Symposium on Lysosomal Storage Disorders, Madrid, Spain	2 days
April 7, 2011	Canadian Society of Nephrology Annual Meeting, Vancouver, BC	1 day
April 8-11, 2011	World Congress of Nephrology, Vancouver, BC	4 days
April 12-14, 2011	Focus on Fabry Nephropathy: Biomarkers, Progression and Treatment Opportunities, Satellite Meeting to the WCN, Vancouver, BC	2 days
May 31, 2011	Canadian Fabry Disease Treatment Guidelines Committee Meeting Vancouver, BC	½ day
June 1, 2011	Canadian Fabry Disease Initiative Study Annual Meeting, Vancouver, BC	1 day
June 2-3, 2011	LSD Club Meeting, Vancouver, BC	1½ days
August 5, 2011	5th Replagal Anniversary Meeting in Argentina: Making History in Fabry Disease, Buenos Aires, Argentina	1 day
Oct. 14, 2011	Transplant Atlantic Annual Meeting, Halifax, NS	1 day
Jan. 26-27, 2012	Course on Neurologic Complications of Fabry Disease. Lysosome Centre, Academic Medical Center, Amsterdam, The Netherlands	1½days
Feb. 8-10, 2012	8 th Annual WORLD Meeting, San Diego, CA USA.	3 days
Mar. 2,3, 2012	11 th International Workshop on Lysosomal Storage Diseases, London, UK.	2 days
April 27-29, 2012	Canadian Society of Nephrology Annual Meeting, St. John's, NL	2½ days
May 10,11, 2012	Lysosomal Storage Diseases Club Meeting, Toronto, ON	1½ days
June 6, 2012	Canadian Fabry Disease Treatment Guidelines Committee Meeting, Halifax, NS	½ day

June 7, 2012	Canadian Fabry Disease Initiative Study Annual Meeting, Halifax, NS	1 day
June 8, 2012	Shire Advisory Board Meeting: Exploring the current and future state of ERT in Fabry Disease, Halifax, NS.	1 day
Sept. 28,29, 2012	Fabry Expert Workshop, Mexico City, Mexico.	1½ days
Oct. 12,13, 2012	Fabry Expert Lounge Meeting, Munich, Germany.	1½ days
Nov. 25, 2012	Fabry Disease Advisory Board Meeting, Frankfurt, Germany.	1 day
Jan. 23, 24, 2013	Sphinx Education Program Workshop: Cardiac Manifestations in Fabry Disease. Academic Medical Center, Amsterdam, the Netherlands.	1½ days
Feb. 13-15, 2013	9 th Annual WORLD Symposium, Orlando FL, USA	3 days
April 6, 2013	Internal Medicine Day, Bridgewater, NS	½ day
May 9, 10, 2013	LSD Club meeting, Montreal, QC	1½ days
May 10, 2013	Canadian Fabry Disease Treatment Guidelines Committee Meeting Montreal, QC	½ day
May 11, 2013	Canadian Fabry Disease Initiative Study Annual Meeting, Montreal, QC	½ day
June 4, 5, 2013	Third Update on Fabry Nephropathy. Biomarkers, Progression and Treatment Opportunities. Hong Kong, China.	1½ days
June 7, 2013	Kidney and Lipids, World Congress of Nephrology Satellite Symposium, Fukuoka, Japan.	1 day
Sept. 3, 2013	Shire Fabry Disease Advisory Board Meeting, Barcelona Spain	1 day
Sept. 4-6, 2013	12 th International Congress of Inborn Errors of Metabolism, Barcelona, Spain	2½ days
Nov. 2, 2013	CFDI Study Scientific Committee Meeting, Toronto, ON	½ day
Nov. 7-10, 2013	American Society of Nephrology Annual Meeting, Atlanta, GA USA	3½ days
Nov. 20, 2013	Nordic and Baltic Fabry Meeting, Oslo, Norway	1 day

Feb. 10, 2014	Genzyme Lysosomal Storage Diseases Advisory Board, San Diego, CA USA	½ day
Feb. 11-13, 2014	10 th Annual WORLD Symposium, San Diego, CA USA.	3 days
March 21-22, 2014	Fabry Expert Lounge Meeting, Rome, Italy.	1½ days
May 1, 2014	Research Day, Department of Medicine, Dalhousie University, Halifax NS	½ day
May 16-17, 2014	Fabry Master Class IV Meeting, Prague Czech Republic	2 days
May 31-June 3, 2014	European Renal Association-European Dialysis and Transplant Association 51 st Annual Meeting, Amsterdam, the Netherlands.	4 days
June 4, 2014	First Fabry Expert Day in Nephrology, Amsterdam the Netherlands	1 day
June 20, 2014	Scientific Committee Meeting, CFDI Study, Vancouver BC	2 hours
June 21, 2014	Canadian Fabry Disease Treatment Guidelines Committee Meeting Vancouver BC	½ day
June 21, 2014	Canadian Fabry Disease Treatment Initiative Study Annual Meeting Vancouver BC	½ day
Aug. 28-29, 2014	Ist LATAM Fabry Masterclass Meeting. Buenos Aires, Argentina.	2 days
Nov. 1, 2014	FACTS study meeting, Langdon Hall, Cambridge ON.	1 day
Nov. 21, 22, 2014	European Symposium on Lysosomal Storage Disorders, London UK.	2 days
Feb. 9, 2015	Genzyme Lysosomal Storage Diseases Advisory Board, Orlando FLA, USA	½ day
Feb. 10-12, 2015	11 th Annual WORLD Symposium, Orlando FLA, USA.	3 days
Mar. 13-14, 2015	Fabry Round Table Meeting, Paris, FR.	1½ days
Apr. 16, 2015	The Hamlet Study Symposium. Fabry or not Fabry. From Genetics to Diagnosis. Academic Medical Center, Amsterdam, The Netherlands.	1 day
May 7, 2015	Lysosomal Storage Disease Club Meeting, Rimrock Hotel, Banff AB.	

		1 day
May 9, 2015	Fabry Masterclass Meeting, Warsaw, Poland.	1 day
May 28-31, 2015	European Renal Association-European Dialysis and Transplant Association 52nd Annual Meeting, London UK.	4 days
June 1-2, 2015	4th Symposium on Fabry Nephropathy, a Satellite meeting of the European Renal Association/European Dialysis and Transplant Association. Manchester UK.	2 days
June 13, 2105	Annual Meeting of Chinese Medical Association, Symposium on Fabry Disease. Taipei, Taiwan.	½ day
Oct. 15-17, 2015	KDIGO Controversies Conference on Diagnosis and Management of Patients with Fabry Nephropathy, Dublin IE.	
Oct. 23,24, 2015	European Symposium on Lysosomal Storage Diseases, Barcelona SP.	2 days
Nov. 6-9, 2015	American Society of Nephrology Annual Meeting, San Diego CA USA.	3½ days
Jan. 9, 2016	CFDI Scientific Committee Meeting, Montreal QC	1 day
Mar. 1-3, 2016	12 th Annual WORLD Symposium, San Diego CA, USA.	3 days
Mar. 12, 2016	Annual Scientific Committee meeting FACTS study, Langdon Hall, Cambridge ON	1 day
April 7, 2016	Department of Medicine, Dalhousie University Annual Research Day, Pier 21, Halifax NS	½ day
April 15, 2016	Protalix Research Meeting, New York, New York USA.	1 day
April 22-23, 2016	Fabry Masterclass VIII Meeting, Riga, Latvia	1½ days
May 8, 2016	Canadian Fabry Association Annual Meeting, Halifax NS	1 day
May 14, 2016	Canadian Society of Nephrology Annual Meeting Halifax NS	1 day
May 18, 2016	Canadian Fabry Disease Initiative Annual Scientific Meeting Halifax NS	½ day
May 18, 2016	Canadian Fabry Disease Treatment Guidelines Review Committee Halifax NS	½ day

May 19-21, 2016	Garrod Symposium 2016, Halifax NS	2½ days
June 16, 17, 2016	Lysosomal Storage Diseases Club meeting, Toronto ON	2 days
July 7-10, 2016	The Pathobiology of the Lysosome and Lysosomal Diseases Conference, Cambridge University, Cambridge UK	3½ days
Sept. 24-25, 2016	Asian Fabry Disease Master Class Meeting. Seoul, South Korea.	1½ days
Feb. 13, 2017	Amicus Advisory Board, San Diego CA, USA.	½ day
Feb. 14-16, 2017	13 ^h Annual WORLD Symposium, San Diego CA, USA.	3 days
April 7, 2017	5 th Annual Langdon Hall Meeting on Gene Transfer Therapy in Fabry Disease, Cambridge ON, Canada.	1 day
April 25-27,2017	5th Symposium on Fabry Nephropathy, a Satellite meeting of the World Congress of Nephrology, Mexico City, Mexico.	2 days